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Effective treatment of many CNS diseases remains a major challenge due to the lack of 
specificity for therapeutics to target pathological cells. Many nanoparticles offer promising 
approaches for controlled, sustained release of therapeutics, yet their applications are limited by 
the lack of knowledge on how they interact with pathological cells. Microglial cells play a key 
role in mediating the development of many CNS diseases. In this thesis, we investigated the 
mechanism for Polyamidoamine (PAMAM) dendrimers (dendrimers) to target microglial cells in 
different pathologies (e.g. malignant brain tumor, neuroinflammation) that are commonly 
observed in many CNS diseases. Building from this knowledge, we developed dendrimer-based 
therapeutics that can target microglia and improve therapeutic efficacy in CNS diseases. 
We first determined the mechanism for dendrimers to target microglia in malignant brain 
tumor and neuroinflammation. In malignant brain tumor, we found systemically delivered 
dendrimers can target tumor and Tumor Associated Macrophages (TAMs) within 15 minutes and 
4 hours respectively after administration. In the presence of neuroinflammation, dendrimers can 
cross the Blood-Brain Barrier (BBB) and selectively localize in ‘activated’ microglia at different 
stages of activation. Further ex vivo study revealed that, although these ‘activated’ microglial 
cells had impaired movement, they tended to take up dendrimers more rapidly and to a greater 
extent compared to the microglia under physiological conditions.  
We then sought to investigate the physiochemical properties of dendrimer that can affect its 
intrinsic targeting to the CNS diseases. We found increase dendrimer size from generation 4 
(G4) to generation 6 (G6) can increase its tumor uptake 100-fold, while still maintaining its 
intrinsic targeting to TAMs. Cationic dendrimers demonstrated the highest brain accumulation, 
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following with neutral and anionic dendrimers, yet only neutral dendrimers were able to diffuse 
within the brain parenchyma and target ‘activated’ microglia. 
Based on these design criteria, we formulated therapeutic dendrimer through covalently 
conjugating a glutamate carboxypeptidase II inhibitor (i.e. 2MPPA) to dendrimers (D-2MPPA), 
using disulfide bond as a linkage. When evaluated in a clinical translatable rabbit model of 
cerebral palsy, D-2MPPA demonstrated higher brain accumulation and specific glial cell-
targeting compared with free 2MPPA. This targeted delivery efficiently inhibited glutamate 
excitotoxicity, attenuated neuroinflammation, and subsequently improved neurobehavior, with 
clinical significance.  
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1. BACKGROUND AND INTRODUCTION1 
1.1. Nanotechnology and CNS diseases  
Achieving effective therapy for many diseases in the central nervous system (CNS) remains 
a great challenge. To date, clinical treatments for CNS diseases provide only limited 
improvement in outcomes and are often accompanied by severe side effects. For instance, 
patients diagnosed with glioblastoma only have a median survival period of 14 months following 
surgical resection, radiation, or concomitant chemotherapy [1]. The difficulty in achieving 
improved outcome for CNS diseases stems from the inability to deliver therapeutically relevant 
doses of the therapeutic to diseased cells or regions. The Blood-Brain Barrier (BBB) poses as the 
main obstacle that prevents most systematically administrated drugs from entering the CNS.  
Nanomedicine offers great potential for improving the therapeutic efficacy or diagnosis 
efficiency in the clinical settings for many CNS disorders. The use of nanoparticles as drug 
delivery vehicles is not only widely reported in pre-clinical studies but is now also being 
implemented in clinical applications. While the entry of drugs to the brain is highly restricted, 
drug-carrying nanoparticles can significantly improve the CNS pharmacokinetics and 
biodistribution relative to free drugs [2]. Recent discoveries have shed more light on the CNS 
disease pathology at the cellular or even molecular level, and have greatly impacted the design of 
nanomedicine to target specific cell populations in the CNS. This review will describe the 
pathological roles of major CNS cells (such as neurons, microglia/macrophage, astrocytes, 
endothelial cells, and brain tumor cells) in CNS disorders. We will then focus on recent advances 
                                                          
1 Parts of this chapter appears in F. Zhang, Y.A. Lin, S. Kannan, R.M. Kannan, Targeting specific cells in the brain with 
nanomedicines for CNS therapies. J Control Release, 2015 Dec 11. pii: S0168-3659(15)30265-0. 
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of nanomedicine design that have been implemented to target specific cell populations in the 
CNS. 
1.2. Blood-brain barrier under physiological and pathological conditions 
1.2.1 BBB under normal physiology 
The BBB is composed of endothelial cells adjoined with tight junctions which act as 
physical barriers and constrain the passage of most molecules through the barrier to transcellular 
trafficking. More than 98% of small molecular drugs and almost 100% of large-molecules (>500 
Da) are simply excluded from CNS because they cannot cross the BBB [3]. It not only functions 
as a protective obstruction that blocks possible neurotoxic substances from CNS but also 
mediates several important functions, such as i) selectively transporting molecules that provides 
essential nutrients to the brain, ii) effluxing waste products, and iii) regulating homeostasis in the 
brain [4].  
Small molecules are known to pass through endothelial cells by passive diffusion (for 
lipophilic molecules) or by active transport (as in the case of required nutrients into the brain, 
such as glucose, amino acids, nucleosides, or nucleobases) [4]. Small lipophilic molecules (<400 
Da) exhibit certain abilities to pass the BBB by passive diffusion through the endothelial cells 
[5]. Unfortunately, many therapeutic molecules do not belong to this category. Most 
hydrophobic substances over 400 Da fail to enter the brain through this mechanism, often due to 
the efflux system regulated by ATP-binding cassette (ABC) transporters [5, 6]. These 
transporters are protective mediator that actively exclude possible neurotoxic substances from 
entering the CNS and are expressed on the endothelial cells. For instance, P-glycoprotein, an 
ATP-dependent transport protein localized in the blood luminal membrane, deters the entry of 
potentially toxic substances by pumping them back to the blood. While many small molecular 
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drugs are substrates of ABC transporters, they possess fairly limited capabilities of entering the 
brain.  
Large molecules, peptides or proteins, are incapable of passive diffusion across the BBB. 
Thus, their preferred mode of transport is through transcytosis, given that endothelial cells at the 
BBB exhibit much lower activity of internalization compared with other endothelia [4]. This 
mechanism involves either adsorptive-mediated (non-specific) or receptor-mediated (specific) 
transcytosis to allow macromolecules, captured in vesicles, to be internalized by endothelial cells 
and eventually exocytosed into the brain [4]. Adsorptive transcytosis involves endothelial 
internalization induced by non-specific binding caused by the interaction between cell surface 
and excess positive charges on the macromolecules. Some cationic proteins or peptides, such as 
cationic albumin, undergo this type of pathway to cross the endothelial cells [7]. On the other 
hand, internalization of substances can also occur by receptor-mediated transcytosis when 
ligands interact with their respective endothelial membrane receptors, such as transferrin receptor 
(TfR), melanotransferrin receptor (MTfR), lactoferrin (LfR), or LDL-receptor-related proteins 
[8, 9, 10, 11]. Researchers that have designed nanomedicines in an attempt to increase drug 
delivery to the brain have heavily considered these two pathways, as discussed later. 
1.2.2 BBB under pathological conditions 
Dysfunction of BBB endothelial cells is an important feature in many CNS pathologies [12]. 
This dysfunction is often associated with neuroinflammation which leads to alternation of 
permeability of the BBB. Under these conditions, the tight junctions between endothelial cells 
are disrupted, which enables additional substances to cross BBB or permits circulating 
macrophages to infiltrate into the CNS (Figures 1.1 and 1.2). This permeability change can be 
observed in neuroinflammation initiated by bacterial lipopolysaccharides (LPS), or in disease 
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pathologies for stroke, traumatic brain injury, MS, and brain tumors [4, 13]. However, the degree 
of impairment is controlled by the pathology of different diseases, and the severity of the disease 
and the maturation of blood brain barrier. [14] In brain cancer, the poorly developed BBB leads 
to the formation of gaps and extensive fenestration [15]. As a result, an increased permeability of 
BBB was observed. As one of the main characteristics of brain tumor, the leakage of blood brain 
tumor barrier (BBTB) is highly heterogeneous, significantly difference was reported between 
tumor core and tumor border [16] and the upper limit of gaps in BBTB can varied from 20-
100nm [17]. In some diseases such as AD or PD, the BBB permeability is altered due to 
decreased level of P-glycoprotein expression, which lowers the efficiency of efflux pumps in 
transporting neurotoxic substances back to the blood [18, 19, 20, 21, 22]. In brief, the altered 
properties of blood brain barrier created opportunities for delivering therapeutics across BBB and 
reach the pathologic location, however, to better take advantage of this, a thoroughly 
understanding of nanoparticles relation with BBB is required. 
1.3. Microglia and their role in CNS diseases 
1.3.1. Microglia in Neurodegenerative Diseases 
The CNS possesses a distinctive immune system since circulating immune cells cannot 
access to the CNS in physiological conditions. Microglial cells serve as the major resident 
immune cells in the CNS where they constantly monitor their surroundings and act as the 
mediator in innate immunity for early control of infections [23, 24]. They serve as key 
therapeutic targets because their functions are closely associated with the pathologies of many 
CNS disorders, including ischemic stroke, traumatic brain injury, spinal cord injury, AD, 
Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and most 
types of brain tumors [23, 24, 25, 26, 27, 28, 29]. Under normal conditions, quiescent microglial 
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cells constantly survey their surroundings, providing a defense mechanism for the brain. Upon 
sensing pathogen invasion or tissue damage, they rapidly switch to the activated phenotype that 
secretes cytokines to initiate secondary inflammatory responses. (Figure 1.1). This phenotype 
change of microglia, characterized by a morphological change from ramified form to amoeboid 
form, is often induced by the recognition of pathogen-associated moieties by toll-like receptors 
(TLRs), a family of receptors that plays a role in both innate and adaptive immunity [23, 24]. 
When recognizing stimuli by such receptors, microglia can produce cytokines to stimulate either 
pro-inflammatory or anti-inflammatory responses. It should be noted that the termed “activation” 
could indicate a range of activated states for microglia, broadly divided into two main 
phenotypes, M1 and M2, as indicated in other reviews [30, 31]. Activated microglia in the M1 
state, or also called “classically activated”, promote the production of inflammatory cytokines, 
such as TNF-α, IL-1β, or IL-6 [23, 24]. On the other hand, M2 microglia contain phenotypes 
which suppress inflammation by cytokines TGF-β or IL-10 (M2a phenotype), or assist tissue 
remodeling and matrix deposition (M2c phenotype) [30]. The dynamic between M1 and M2 
phenotypes of microglia enables the response to early stages of infection and is responsible for 
the clearance of cellular debris. However, in many pathological conditions, pro-inflammatory 
effects can persistently dominate without effective anti-inflammatory responses. For example, 
M1 microglia may release cytotoxic nitric oxide (NO), reactive oxygen species (ROS), or 
excessive cytokines (such as TNF-α) that cause neurotoxicity and lead to the injury/death of 
neurons, oligodendrocytes, and/or damage extracellular matrix [31]. 
 Dysfunction of microglial responses has been observed in CNS diseases associated with 
both acute and chronic neuroinflammation. In acute inflammation, such as ischemic stroke, 
spinal cord injury, or traumatic brain injury, microglia activation is triggered by mechanisms that 
            
             
22 
 
cope with damage-associated molecular pattern molecules (DAMPs) released from injured cells 
or cellular necrosis processes [32, 33]. Though this is a crucial step for tissue repair, a failure of 
follow-up anti-inflammation responses in these instances can result into more damages. As stated 
before, this activation (dominated by M1 phenotype) could lead to over-production of cytotoxic 
NO and ROS, which exacerbate the cellular death, or cytokines (for example, IL-1, IL-6, and 
TNF-α) that amplify inflammation response [34]. Chronic inflammation, in contrast to acute 
inflammation, is a self-propagating inflammatory response initiated from certain stimuli. This 
process generally starts from an initial microglia activation, which further develops into 
increased inflammation and glial activation when M2 responses occur and fail to exert their 
neuroprotective roles [30]. M1 microglia participates in the chronic inflammation of many 
neurodegenerative diseases, including AD, PD, ALS, or MS [29, 35, 36, 37]. In these instances, 
microglia respond to stimuli, such as aggregation of Aβ in AD and α-synuclein in PD, motor 
neuronal death in ALS, or signals from infiltrating lymphocytes in MS; and further produce more 
NO, ROS, proinflammatory cytokines (such as TNF-α, IL-1β, IL-6) that eventually cause 
progressive injury to other neurons/astrocytes without appropriate neuroprotective effects from 
M2 phenotypes [29, 30, 31, 38, 39, 40, 41]. Since this cascade is often accompanied with BBB 
impairment in pathology, circulating macrophages can possibly infiltrate into the CNS and 
function similarly to microglial cells to amplify the inflammatory responses. 
The production of proinflammatory cytokines and neurotoxic substances from 
microglia/infiltrating macrophages are linked to several pathways, including, but not limited to, 
the activation of NOX2 complex (an NADPH oxidase), mitogen-activated protein kinase 
(MAPK), and sphingosine kinase 1 (Sphk1) as detailed elsewhere [42, 43, 44]. In general, these 
pathways can be stimulated by variety of disease proteins (Aβ precursor protein, α-synuclein, 
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myelin), LPS, cytokines (TNF-α, IL-1β, IL-4, IL-13), or environmental toxins. Since these 
pathways account for the production of neurotoxic molecules, inhibition of these pathways in 
microglia can possibly promote neuroprotective effects. For example, inhibition of NOX2 or p38 
MAPK by treating dexamethasone or minocycline could attenuate the activation of microglia, as 
well as the production level of NO and IL-1β [43, 45, 46]. Dimethylsphingosine, an inhibitor of 
Sphk1, reportedly suppresses the expression of proinflammatory cytokines including TNF-α, IL-
1β, and the production of NO of microglial cells [44]. But to optimize the therapeutic effects, 
these potent drugs require specific, effective delivery to microglia/infiltrating macrophages. 
1.3.2. Tumor-Associated Microglia/Macrophages in Tumor Microenvironments 
Tumor-associated microglia and infiltrating macrophages (TAMs) pose as important 
mediators in CNS cancer (Figure 1.2). Various studies regarding the synergic effects between 
TAMs and gliomas that allow them to co-exist have been reviewed previously [25, 47]. TAMs 
can be recruited by gliomas by chemokines, cytokines, or matrix metalloproteinases 
(MMPs)[25]. Although TAMs may polarize to M1 phenotype to give rise to pro-inflammatory 
effects (for initiating the clearance of potential hazards in CNS), their inflammatory functions are 
often suppressed in glioma pathology [27, 47, 48, 49, 50]. Gliomas produce anti-inflammatory 
cytokines such as IL-10, IL-4, IL-6, and TGF-β [25], where tumor cells are able to establish an 
immunosuppressive microenvironment after recruiting TAMs. Under such condition, TAMs are 
instead polarized to the M2 phenotype that reduces classic neuroinflammation, and allows 
further tumor progression [25, 47]. In addition, TAMs themselves can also secrete cytokines 
(TGF-β) and MMPs (MMP-2, MMP-9, and MT1-MMP) that promote tumor growth and 
invasion [51, 52, 53, 54]. These findings suggest TAMs can serve as a crucial target, as their 
pathological functions are strongly associated with tumor cells. Delivering therapeutics to alter 
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the functions of TAMs or using TAMs as delivery vehicles could potentially provide an effective 
approach for the treatment of brain tumors. 
1.4. Polyamidoamine (PAMAM) dendrimers and dendrimer-based drug delivery 
1.4.1. Introduction to PAMAM dendrimer-the physical and chemical properties 
Dendrimers are branched polymeric molecule with nanoscale size (between 3 to 20nm), 
nearly monodispersity (polydispersity index close to 1.0), and well-defined architecture. The 
name ‘dendrimer’s is a figurative representation of dendrimer’s tree like branched structure with 
‘dendros’ meaning tree and ‘meros’ meaning part. The structure of dendrimer usually consists of 
a repetitive sequence of monomers, called branching units (dendrons); a core unit where the 
branching units are growing from in a radial iterative fashion; and a terminal group which is at 
the end of growing branching units. This controlled step-by-step synthesis contributes to 
dendrimer’s extremely controllable physical and chemical properties [55, 56]. 
Among the large dendrimer family, Polyamidoamine (PAMAM) dendrimer is the most 
extensively characterized and widely used, and it is the first commercialized dendrimer. They are 
synthesized via Michael addition of amino groups of ethylene diamine (EDA) core with methyl 
acrylate (branching unit), followed by amidation of the resulting esters with EDA, forming 
generation 0. Repetition of these two synthetic steps leads to next generations. The size of 
dendrimer grows linearly in diameter as a function of generations, with an increase of ~1nm for 
each generation. While the surface functional group and molecular weight gets doubled as the 
increase of generation [55]. 
PAMAM dendrimers have high density of surface functional groups that can be tailored. For 
example, the surface ζ potential of dendrimers can vary from positive to negative as the surface 
functionality change from amine (13.94±1.5 mV) to hydroxyl (−3.4±1.2mV) and carboxyl 
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(−13.0±1.1mV) [57]. Although PAMAM dendrimers have globular structure in general, their 
conformation change with the chemical environment such as pH, ionic strength and the polarity 
of solvent, especially the pH level. Under low pH (~3) environment, the protonated amine 
groups will lead the whole structure to a more extended conformation due to the electrostatic 
repulsion between the positively charged NH3
+
 groups; under neutral pH, backfolding occurs due 
to the uncharged interior tertiary amine and the charged surface primary amine, while at basic pH 
the higher backfolding effect will lead to a more globular confirmation [58]. 
1.4.2. Dendrimer as drug delivery vehicle 
The highly tailorable surface functional groups and comparatively hydrophobic core make it 
possible to either modify the surface or conjugate/complex therapeutics or encapsulate them.  
Specifically, many studies conjugate drugs to the terminal functional groups of dendrimer 
through covalent bond using different linking chemistry; the surface of positively charged amine 
terminated dendrimer can also be used to complex with negatively charge gene therapies; modify 
the surface of dendrimer using polyethylene glycol (PEG) or targeting ligand such as folic acid 
can help to achieve desired biological effect. Moreover, the interior of dendrimer can be used to 
physically entrap guest molecules to achieve drug delivery function. These features make 
dendrimer ideal drug carriers with high drug payload capacities [59]. 
PAMAM dendrimers also possess the good barrier penetrating properties to many biological 
barriers such as the intestines, the blood-tissue barriers and so on. Take the transepithelial 
property of dendrimer for example. Studies have shown PAMAM dendrimer are transported by a 
combination of paracellular and transcellular routes, in which dendrimer can open the tight 
junctions of epithelial barriers (paracellular transport), and enter/leave the cell through a variety 
of endocytic mechanisms (transcellular transport) [60]. The first evidence of dendrimer targeting 
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penetrating BBB in vitro was observed by Bhadra using PEGylated Generation 4 PAMAM 
dendrimer [61]. The mechanism behind dendrimer’s BBB penetrating property was suggested in 
later studies: 1) the high density of surface charge can interact with BBB endothelium and cause 
the disruption; 2) the nanoscale of dendrimer enhanced the entry of dendrimer and by inhibiting 
the efflux P-glycoproteins [62]. 
The toxicity of PAMAM dendrimer is associated with many of their physical properties 
such as size, shape and chemical properties such as the surface functional groups [63]. In 
PAMAM dendrimer, amine terminated generation 4 dendrimer (G4-NH2) have a higher dose 
dependent in vivo toxicity than hydroxyl terminated dendrimer of same generation (G4-OH). [64, 
65, 66] G4-NH2 showed toxicity at dose of 30 mg/kg, while G4-OH showed toxicity only at dose 
of 1000 mg/kg [58]. The result in this in vivo study is consistent with previous in vitro studies, 
which reported that cationic dendrimers are cytotoxic and can destabilize cell membrane, cause 
cell lysis [67, 68]. Similar studies also focused on the size/generation dependent in vivo toxicity 
of PAMAM dendrimer. For PAMAM dendrimer, higher generation in general exhibits higher 
toxicity. [58, 60, 61, 69]. These results are in agreement with the results of in vitro 
size/generation depend cytotoxicity studies [65, 66]. However, in vitro studies can only give 
relative index of potential toxicity of PAMAM dendrimers. The ultimate toxicological profile 
will depend on its pharmacokinetics study in vivo. Previous studies on amine terminated 
PAMAM dendrimer showed G7-NH2 has a higher accumulation in the liver while most G4-NH2 
was eliminated by the renal clearance. This result in biodistribution explains the data in toxicity 
in same study, which indicates that the hepatic hemorrhage and hemobilia after G7-NH2 
administration is related to high liver accumulation [58]. Except for surface charge, dendrimer 
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chemistry and generation/size, some other factors such as administration routes, animal model 
can also influence the result of dendrimer toxicity.  
  
            




Figure 1.41. Common features in neuroinflammation. 
In general, microglial cells are initially activated by injury signals, such as damage-associated 
molecular pattern molecules and cell debris from damaged cells in acute inflammation, 
aggregates of Aβ in Alzheimer’s disease, α-synuclein aggregates from abnormal dopaminergic 
neurons in Parkinson’s disease, SOD1 aggregates from diseased neuron in amyotrophic lateral 
sclerosis. In such pathologies, microglia (together with infiltrating macrophages) tend to polarize 
to M1 phenotype that amplifies neuroinflammation by producing pro-inflammatory cytokines 
(TNF-α, IL-1β, IL-6) as well as ROS and NO which lead to neuronal injury. Some pro-
inflammatory cytokines (such as TNF-α, IL-1β) can also activate astrocytes to induce over-
production of ROS and NO that exacerbate the injury. The impaired neurons are then susceptible 
to undergo apoptosis or necrosis, which, in turn, release molecules that further activate 
microglia. 
            




Figure 1.42. Role of tumor-associated microglia/macrophages and tumor cells in tumor 
microenvironment. 
Glioma cells generally create an environment that suppresses classic inflammation (or, the 
functions of M1 phenotypes of microglia/infiltrating macrophage) by cytokines such as TGF-β, 
IL-10, IL-4, IL-6. Microglia/macrophages, under such circumstance, are polarized to M2 
phenotypes and produce cytokines (TGF-β) or MMPs that are associated with tumor progression.  
            









Malignant glioma is the most common and most aggressive primary brain tumor [70] and 
despite the advances in treatment, the median survival remains at 16.4 months [71]. Key 
challenges faced in the development of effective therapies relate to (a) the ability of systemically 
delivered chemotherapeutic agents to penetrate the impaired blood-brain tumor barrier (BBTB) 
and provide coverage across the entire solid tumor [72] and (b) the ability to target specific cells. 
Although small molecule-based therapeutics can effectively distribute within the tumor tissue, 
they are limited by rapid tumor clearance [73] and off-target extravasation, potentially leading 
to adverse effects [72]. Recent advances in nanotechnology have provided selective tumor 
accumulation. However, the size of most nanoparticles limits extravasation and tumor 
penetration, thus limiting homogeneous solid tumor coverage [72, 74]. Careful tuning of particle 
size and surface charge has been attempted in order to enhance the nanoparticle distribution 
profile in subcutaneous tumors [75], [76], [77, 78]. Unfortunately, achieving homogeneous 
coverage of orthotopic brain tumors has been proven even more challenging. This may be 
attributed to the lower permeability of the BBTB compared to the blood-tumor barrier (BTB) in 
a subcutaneous tumor, the heterogeneous intervascular spaces and the high interstitial pressure in 
brain tumors. Although, some strategies have attempted nanoparticle delivery through the BBTB 
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via absorptive uptake; passive diffusion through the leaky BBTB fenestrations has only been 
demonstrated with molecules smaller than 20 nm [79, 80, 81, 82] and unhindered diffusion 
through the BBTB has been achieved with molecules of 7 nm [83], thus limiting the relevance of 
most nanoparticle-based therapeutics. 
Hydroxyl-terminated generation 4 polyamidoamine (PAMAM G4-OH) dendrimer is a 
highly tailorable branched macromolecule with a hydrodynamic size (~4 nm) smaller than 
conventional nanoparticles and near-neutral surface charge (ζ-potential: +4.5 ± 0.1 mV), 
physicochemical attributes that may allow for effective BBB [84] and tumor extra cellular matrix 
(ECM) penetration [85]. We have previously shown that, without the use of targeting ligands, 
these dendrimers can target activated microglia/macrophages after passing the impaired blood-
brain barrier (BBB) in a rabbit model of cerebral palsy [86]. This targeted accumulation resulted 
in a significant efficacy when the dendrimer was conjugated to N-acetylcysteine [86]. In glioma, 
tumor associated microglia/macrophages (TAM) have been shown to participate in tumor 
growth, tumor invasion, angiogenesis and immune system evasion [47]. A variety of 
microglia/macrophage modulating molecules has been shown to decrease glioma progression 
and increase survival in preclinical studies [87], [88], [89, 90]. Therefore, nanoparticle targeting 
of TAM has been explored, through the use of different ligands [91], [92], [93, 94]. 
We investigated the use of PAMAM G4-OH dendrimer as a promising therapeutic vehicle 
for the treatment of malignant glioma. A recently developed fluorescence-based ‘quantification’ 
approach and high resolution confocal microscopy were combined to investigate the kinetics, 
biodistribution and clearance of these dendrimers in a 9L gliosarcoma intracranial tumor model. 
We also characterized the dendrimer’s intrinsic ability to selectively target TAM. 
 
            




2.2. Materials and Methods 
2.2.1.  Materials and reagents 
The following agents were purchased: hydroxyl terminated ethylenediamino-core PAMAM 
dendrimer (referred to as dendrimer throughout, unless otherwise specified) (Dendritech, 
Midland, MI), Methanol (HPLC grade), DMF (HPLC grade), stainless steel beads (Fisher 
Scientific, Waltham, MA); and Cyanine 5 (Cy5) (GE Healthcare Life Science, Pittsburgh, PA). 
For confocal microscopy: nuclei counterstain, 4',6-diamidino-2-phenylindole, dihydrochloride 
(DAPI), Alexa Fluor® 594 Goat Anti-Rabbit IgG (H+L) Antibody (Molecular Probes, Eugene, 
Oregon);  Fluorescent mounting media (Dako, Santa Clara, CA); Anti-Iba1, Rabbit (Wako, 
Osaka, Japan);  Lectin from Bandeiraea simplicifolia (BSI-B4) (Sigma-Aldrich, St. Louis, MO); 
Anti-GFAP 488 (eBioscience, San Diego, CA); Fluorescein isothiocyanate–dextran (FITC-
dextran), average molecular weight 70,000 Da (Sigma Aldrich, St. Louis, MO). 
2.2.2. Synthesis of dendrimer Cy5 (D-Cy5) conjugates 
D-Cy5 was prepared through two steps following a previously published method [95]. 
Briefly, hydroxyl-terminated PAMAM dendrimer was surface-modified with amine groups to 
make a bifunctional dendrimer. We used 6-(Fmoc-amino)caproic acid  to produce a Fmoc-
protected bifunctional dendrimer intermediate that was eventually de-protected by re-dissolving 
in a mixture of piperidine/DMF. Cy5 dye with N-hydroxysuccinimide monoester was reacted 
with amine groups on the surface of bifunctional dendrimer. The ‘crude’ products were further 
extensively purified by dialysis. The final D-Cy5 conjugate was characterized using 1H NMR, 
high-performance liquid chromatography (HPLC) and gel permeation chromatography (GPC). 
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The conjugate was stored as a solid powder at -20 °C and reconstituted at 10 mg/mL with sterile 
0.9% NaCl solution on the day of administration. 
 
2.2.3. Tumor inoculation 
Female Fischer 344 rats, weighing 125-175 g each (Harlan Bioproducts, Indiana, IN), were 
housed in standard facilities and given free access to food and water. 9L gliosarcoma intracranial 
implantation was performed as previously described [96]. Briefly, the 9L gliosarcoma (obtained 
from the Brain Tumor Research Center, UCSF, San Francisco, CA) maintained in the flank of 
F344, was surgically excised sectioned into 1 mm3 pieces and placed in sterile 0.9% NaCl 
solution on ice for intracranial implantation. Rats were anesthetized and a midline scalp incision 
was made to identify the sagittal and coronal sutures. A burr hole was made 3 mm lateral to the 
sagittal suture and 5 mm posterior to the coronal suture. The dura was incised, and using a 
surgical microscope and gentle suction a small cortical area was resected. A tumor piece was 
placed in the resection cavity and the skin was closed using surgical staples. All animals were 
treated in accordance with the policies and guidelines of the Johns Hopkins University Animal 
Care and Use Committee. 
2.2.4. D-Cy5 administration for quantification and immunofluorescence 
Animals were injected in tail vein with a 3 mg/300 µL dendrimer-Cy5 solution. For imaging 
of dendrimer and dextran distribution, 3 animals were co-injected with a 0.9% NaCl solution of 2 
mg D-Cy5 and 2 mg dextran-FITC in 300 µL. 
To study the dynamics of dendrimer accumulation in the tumor brain, D-Cy5 was injected 
into 27 tumor inoculated rats when the average tumor size was 6 mm in diameter and then 
animals were sacrificed at fixed time points (15 min, 1hr, 4 hr, 8 hr, 24 hr, and 48 hr). Magnetic 
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resonance imaging was used to measure intracranial tumor size. Blood was drawn through 
cardiac puncture and immediately centrifuged to collect plasma. Brains were harvested and flash 
frozen on dry ice for fluorescence spectroscopy based quantification or placed in 4% formalin 
solution for immunofluorescence. 
To study the dendrimer cell uptake, D-Cy5 injection was performed in 3 tumor inoculated 
rats and 3 healthy rats, and animals were sacrificed 24 hr after the injection. Brains were 
harvested and placed in 4% formalin for immunofluorescence study. 
To study the pharmacokinetics and biodistribution of dendrimer in plasma and systemic organs 
D-Cy5 was injected into 15 tumor-inoculated rats which were placed in metabolic cages for urine 
collection and animals were subsequently euthanized at fixed time points (15 min, 1hr, 4 hr, 8 hr, 
24 hr, and 48 hr). Organs were harvested and flash frozen on dry ice for fluorescence 
spectroscopy-based quantification or placed in 4% formalin for immunofluorescence. 
2.2.5. Fluorescence spectroscopy 
Fluorescence-based quantification of D-Cy5 conjugates followed our previously published 
protocol [95]. Briefly, 100-150 mg of frozen tissue was homogenized in 1 mL of methanol using 
a homogenizer (TissueLyser LT, Giagen) in 2 mL DNA LoBind Eppendorf tubes and 
subsequently sonicated. Suspensions were diluted to 100 mg/mL and centrifuged at 15,000 rpm 
for 15 min at 4 °C. The resulting supernatants were subjected to fluorescence spectroscopy. 
Importantly, prior studies showed that D-Cy5 was stable in plasma, and could be recovered from 
the tissue intact, without appreciable release of the conjugated Cy5 [95]. 
For brain tissue, precise dissection of the tumor was performed and the peritumoral area 
was defined as up to 1 mm away from the tumor dissection plane. In the contralateral hemisphere 
100 mg of the caudate/putamen with the surrounding white matter area was dissected and used 
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for analysis. For plasma and urine samples, a sample of 100 μL of plasma and urine was mixed 
with 900 μL of phosphate buffer (0.1 M) and analyzed by fluorescence spectroscopy.  
Fluorescence spectra of D-Cy5 conjugates and that obtained from tissue extracts were 
recorded using a Shimadzu RF-5301 Spectrofluorophotometer (Kyoto, Japan). D-Cy5 calibration 
curves were constructed, following every experiment, under different slit widths using the 
maximum emission wavelength of 662 nm after recording spectra from 650 nm to 720 nm with 
excitation wavelength of 645 nm. The D-Cy5 concentration was measured in methanol or 
phosphate buffer (0.1 M) in solutions ranging from 1 ng/mL to 100 µg/mL. The slit width was 
chosen based on the observed fluorescence level of different sample sets. For biological samples 
with low levels of D-Cy5 (i.e. brain, lung, heart), the excitation and emission slit width was set at 
10; for biological samples with high levels of D-Cy5, (i.e. urine and kidney) excitation and 
emission slit width was set at 3. For the remaining biological samples, excitation slit width of 5 
and emission slit width of 10 were used. All calibration curves exhibited linearity with R2 ~ 
0.99. Fluorescence registered from tissue of non D-Cy5 injected healthy and tumor inoculated 
rats was subtracted from the values observed from samples of D-Cy5 injected tissue in order to 
account for tissue autofluorescence. 
Concentration of D-Cy5 conjugate in the brain was expressed in μg per g of tissue. The 
concentration of D-Cy5 conjugate in the other organs was expressed in percentage (%) of 
injected dose per gram of tissue or % of injected dose per organ. Concentrations of the D-Cy5 
conjugate in urine and blood were expressed in % of injected dose per mL or % of injected dose 
in total amount of urine or plasma. Total plasma concentration was calculated based on the 
weight of the animal. The brain and plasma quantification data were analyzed to calculate the 
AUC and the brain to serum ratio.  
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Concentration of D-Cy5 conjugate in the brain was expressed in μg per g of tissue. The 
concentration of D-Cy5 conjugate in the other organs was expressed in percentage (%) of 
injected dose per gram of tissue or % of injected dose per organ. Concentrations of the D-Cy5 
conjugate in urine and blood were expressed in % of injected dose per mL or % of injected dose 
in total amount of urine or plasma. Total plasma concentration was calculated based on the 
weight of the animal. The brain and plasma quantification data were analyzed to calculate the 
AUC and the brain to serum ratio. 
2.2.6. Immunofluorescence 
Freshly harvested tissues were fixed in 4% formalin for 24 hr, followed by a gradient of 
sucrose solutions before cryosection. Tissues were then sectioned transversely into 30 μm-thick 
slices using a Leica CM 1905 cryostat. Slices were stained with DAPI (nuclei), rabbit anti-Iba1 
antibody for microglia/macrophages, and goat anti-rabbit 595 secondary antibody. Some slices 
were stained with isolectin for endothelial cell staining. Slices were then imaged using a confocal 
LSM 710 microscope (Carl Zeiss; Hertfordshire, UK) under 5X, 20X, 40X and 63X 
magnifications. For each slice of tumor-inoculated brains, images where acquired for the tumor, 
tumor border and contralateral hemisphere. For control (non-tumor) brains, 1-3 representative 
images were acquired. Settings were optimized to avoid background fluorescence based on non-
injected control rat brains. Laser power, pinhole, gain, offset and digital gain were selected 
separately for each magnification and kept constant throughout the entire study. 
2.2.7. Software 
For image processing ZEN 2011 software was used, any adjustments in brightness and 
contrast were kept constant throughout the same magnification images. No adjustments were 
done on the Cy5 channel. Imaris software was used for cell counting, co-localization and 
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microglia surface to volume ratio measurements. Microsoft Excel 2010 and KaleidaGraph 4.0 
were used for all calculations, curve fitting and figure plotting related to the pharmacokinetic 
study. 
2.2.8. Cell count and co-localization 
For microglia/macrophage cell count 20X 13×13 tile scan images were analyzed and 3-5 
slices were analyzed per region. The function ‘spots’ was used to identify Iba1+ 
microglia/macrophages. A diameter threshold of 4.15 µm was set to eliminate the objects smaller 
than microglia cells and an intensity threshold of 26.801 based on ‘Quality’ analysis was set to 
eliminate the background signal [97]. 
To study co-localization 40X, 4×4 tile scan images were used and 3-5 slides were analyzed 
per region. The function ‘spots’ was used to identify DAPI+ nuclei, Iba1+ 
microglia/macrophages and D-Cy5+ cells. For cells with D-Cy5 uptake, the spots with D-Cy5 
and DAPI co-localization were counted; for microglia cells with D-Cy5 uptake, the spots with 
DAPI, anti-Iba1 and D-Cy5 co-localization were counted. Estimated diameters were applied to 
eliminate the spots with size smaller than cells, and signal thresholds were applied based on 
‘Quality’ analysis. The function co-localize spots was used by counting the spots where D-Cy5 
signal and cell signal are within 10 μm next to each other [97].  
For surface to volume ratio analysis of the microglia cells, 3D representation of microglia 
morphology was acquired in confocal microscope using 40X magnification, with 3×3 tile scan, 
extending 10 μm in the z direction in z-stack. The function ‘surfaces’ was used and the 
individual Iba1+ microglia/macrophages were analyzed for surface and volume of each cell. 
Tumor area, ipsilateral (non-tumor area), contralateral area, and non-tumor brains were analyzed; 
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approximately 150 cells were included for each region. The threshold settings were based on the 
diameter of cells [98]. 
 
2.2.9. Statistical analysis 
Statistical analysis of data was carried out by student’s t-test and one-way ANOVA 
followed by Games-Howell tests using SPSS 18.0 (IBM, Inc.), as needed. Differences were 
considered statistically significant at p < 0.05. 
 
2.3. Results 
2.3.1. Statistical analysis 
Based on fluorescence confocal microscopy, dendrimer-Cy5 conjugates (D-Cy5) rapidly 
accumulated throughout a 6 mm tumor, as early as 15 minutes after systemic administration. In 
the ‘healthy’ contralateral hemisphere, dendrimers outlined the blood vessels, and were not 
observed in the parenchyma (Figure 2.1A). Fifteen minutes after systemic administration, the 
dendrimers were dispersed throughout the entire intracranial tumor parenchyma. This 
distribution was not influenced by the heterogeneity in the tumor parenchyma (Figure 2.1B). 
There was no appreciable cellular uptake at this time point. At 4 hr post systemic dendrimer 
administration, the extracellular distribution in the tumor region had decreased, which was 
accompanied by an increased uptake by Iba1+ inflammatory cells (Figure 2.1C). The 
contralateral hemisphere showed relatively minimal D-Cy5 fluorescence at all-time points 
(Figure 2.1D,E).  
In order to assess the kinetics of dendrimer accumulation in the brain, we used a recently 
developed fluorescence-based quantification method for D-Cy5. The use of the near IR Cy5 
            
             
39 
 
wavelength overcomes the tissue autofluorescence challenges [95]. The high sensitivity of this 
method (0.1 ng/g of tissue) allowed us to detect dendrimer accumulation at specific anatomic 
locations. In accordance with our confocal microscopy results, dendrimers rapidly accumulated 
in the tumor and peritumoral area within 15 min, with a peak concentration occurring at 8 hr 
(Figure 2.2A). Dendrimers gradually cleared from the tumor at a rate of ~0.01 μg/g/hr, and from 
the peritumoral area at a rate of ~0.007 μg/g/hr, reaching a concentration of 0.2 μg/g of tissue 48 
hr after initial systemic injection (Figure 2.2A). In the contralateral hemisphere, the dendrimer 
accumulation also peaked at 8 hr, at a concentration ~ 8-fold lower than that found in the tumor 
area. At 24 hr, traces of dendrimer (0.03 μg/g) could be detected in the contralateral hemisphere 
and a ~14-fold higher accumulation in the tumor was observed (Figure 2.2A). At 48 hr the area 
under the curve (AUC) was 10 times higher in the tumor area in comparison to the contralateral 
hemisphere, indicating significantly higher (p<0.05) overall exposure of the dendrimer to the 
tumor (Figure 3.2B). The high and selective retention of dendrimer in the tumor and peritumoral 
area was visualized in a low magnification image of the tumor stained for astrocytes 24 hr 
following the administration of dendrimer (Figure 2.2C). 
2.3.2. Time dependent distribution of D-Cy5 in the brain tumor 
To study the dendrimer distribution in the tumor and peritumoral area, we co-injected D-
Cy5 with linear dextran-FITC (70 kDa, ~6.5 nm radius) which has approximately twice the size 
of dendrimer. The tumor was clearly identified based on the increased density of DAPI-positive 
nuclei (Figure 2.3A). At each time point, the dendrimer distributed homogeneously throughout 
the whole tumor region (Figure 2.3B). In comparison, signal from dextran-FITC was only 
observed around the tumor border and not in the tumor core, even though the laser power and 
gain settings were maximized to detect the background signal in the FITC channel (Figure 2.3C). 
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Higher magnification images showed that D-Cy5 rapidly distributed and delineated the ECM 
leading to a reticular pattern of distribution and gradual accumulation in the cells (Figure 2.3D). 
On the contrary, dextran showed limited distribution throughout the ECM but high signal could 
be seen within the blood vessel lumen fifteen minutes after injection. At later time points, limited 
amounts of dextran were retained in the tissue presumably due to low cellular uptake (Figure 
2.3E). 
2.3.3. Characterization of tumor associated microglia/macrophages and cellular uptake of 
dendrimer 
Gliomas produce chemo-attractants and growth factors that promote recruitment and 
proliferation of microglia/macrophages [99, 100]. In human glioblastoma up to 30% of cells can 
be tumor associated macrophages [101]. We characterized the microglial distribution in different 
anatomic locations of the 9L tumor model, which suggested that the concentration of TAM in 
this tumor model is similar to that observed in human glioblastoma. The microglia population 
per mm2 was 9-fold higher within the tumor as compared to the contralateral hemisphere and 
2.5-fold higher in healthy brain tissue of the ipsilateral hemisphere as compared to the 
contralateral hemisphere (Figure 2.4A). 
TAM are reprogrammed in the tumor microenvironment leading to an alternate 
immunosuppressive M2 phenotype [99]. However, a number of studies have suggested sustained 
phagocytic activity of TAM in glioma. The phagocytic activity of TAM has been suggested to 
play a key role in nanoparticle uptake [93, 94]. When microglia/macrophages change from a 
resting to an activated form, their morphology is modified from ramified to amoeboid indicative 
of their increased phagocytic activity [102]. In order to assess the morphology of TAM in the 9L 
tumor model we characterized the surface to volume ratio of the immune cell population (Iba1+) 
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in different anatomical locations [31]. The surface to volume ratio (StoV ratio) is considered a 
‘measure’ of microglial activation [98]. Our results suggest that, indeed, the 
microglia/macrophages within the tumor and surrounding the tumor had a significantly 
(p<0.001) lower StoV ratio in comparison to the immune cells in the contralateral hemisphere, 
and in a healthy brain. The mean StoV ratio for tumor associated microglia was lower than 1, 
indicative of their amoeboid state and phagocytic activity (Figure 2.4B). 
We then quantified the localization of D-Cy5 in the Iba1+ microglia/macrophages cells. At 
24 hr post systemic administration dendrimers localized in the Iba1+. In fact, TAM Iba1+ 
microglia/macrophages were calculated to comprise 38% of the total tumor cell population 
(Figure 2.5A).  Co-localization indicated that approximately half of the TAM population took up 
dendrimers and that the total population of dendrimer-positive cells did not differ quantitatively 
from the population of dendrimer-positive Iba1+ microglia/macrophages. Therefore, dendrimers 
were taken up almost exclusively by tumor associated macrophages within the tumor tissue 
(Figure 2.5A), while other cells within the tumor region didn’t have measurable dendrimer 
uptake. Representative images of cellular uptake of dendrimer in the tumor are demonstrated in 
Figure 2.5B and 2.5C. Interestingly, in the tumor border (indicated as 1mm from the tumor edge 
based on DAPI stain) the dendrimer-positive microglia/macrophages were substantially reduced, 
reflecting the difference in the biological processes between the tumor core and the tumor 
border. Dendrimer was not observed in the ipsilateral non-tumor region or in the contralateral 
hemisphere (Figure 2.5D-F). 
 
            




In this study, we investigated hydroxyl-terminated, generation-4 PAMAM dendrimers as 
potential drug delivery vehicles for the delivery of therapeutics to brain tumors. The systemically 
delivered dendrimers accumulated and were selectively retained in intracranial tumor tissue. 
Moreover, they rapidly and ‘homogeneously’ distributed throughout the entire 6 mm solid tumor 
and peritumoral area, followed by a gradual accumulation in TAM. This suggests that these 
dendrimers may enable selective therapeutic delivery to the brain tumor. 
Small molecule therapeutics may pass the impaired BBTB, but are rapidly cleared from the 
tumor tissue and also distribute in other organs, resulting in limited effect on the tumor cells and 
side effects [103], [104, 105]. Various nanoparticle systems have demonstrated relatively 
selective and sustained accumulation in extracranial tumors and allowed for controlled release of 
chemotherapeutics [75], [77, 106, 107]. However, the size limitation of the BBTB capillary 
fenestrations and the hindered nanoparticle motion in the heterogeneous brain tumor parenchyma 
does not allow for high accumulation and homogeneous distribution in brain tumors [79], [17, 
108]. We show that dendrimers accumulate selectively and rapidly in an intracranial tumor and 
are retained in the tumor for at least 48 hr. Of note, at 4 hr post injection, dendrimer 
accumulation is approximately 10 fold higher in the tumor region compare with the small 
molecule drug doxorubicin [109]. Also, for dendrimers, the AUC(0-24h) in the tumor is 8.5 fold 
higher than that in the contralateral hemisphere, demonstrating improved ‘intrinsic’ targeting in 
comparison to other non-targeted nanoparticle systems and is comparable to actively targeted 
magnetic nanoparticles [110]. Moreover, high concentrations of dendrimer were observed in the 
peritumoral area. The high frequency of glioblastoma recurrence is attributed to high tumor 
infiltration as well as individual cells surviving the initial aggressive treatment. Therefore, 
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achieving high retention in the peritumoral area is important in the design of an effective 
therapeutic vehicle [111].   
Recent studies have maintained that efficient distribution of nanoparticles throughout the 
solid tumor tissue is nearly mandatory for efficacy [112], [113, 114, 115]. The highly 
heterogeneous vasculature of glioblastoma requires the particles to escape the perivascular 
spaces and move a distance of at least 80 nm in order to cover the intervascular spaces [112, 
116]. Perrault et al. have demonstrated that in a subcutaneous tumor model, PEGylated gold 
nanoparticles larger than 20 nm get entrapped in the perivascular spaces [113]. We demonstrate 
that after dendrimers pass through the BBTB, they rapidly distribute through the ECM within 15 
min and cover the entire tumor. This observation can most likely be attributed to the small size 
and near neutral surface charge of the dendrimers that allow them to escape the perivascular 
spaces and penetrate the tumor tissue. 
Our lab has previously reported that non-targeted dendrimers localized in activated 
microglia in the periventricular area of rabbit neonates with neuroinflammation following 
intravenous administration [86]. This selective cellular uptake allowed for therapeutic effect, 
with significant motor function improvement, following delivery of dendrimer-N-acetylcysteine 
conjugates [86]. Of note, this was achieved in spite of only 0.06% of injected dose accumulating 
in the brain, thus, underlining the importance of cell-specific targeting, rather than overall 
accumulation, for improved therapeutic outcome. In the present study we found that 24 hr after 
administration, dendrimers almost completely localized in TAM and that approximately 50% of 
the TAM population had taken up dendrimers. The dendrimers were not seen in ‘non-
activated’/quiescent microglia/macrophages. The high concentration of phagocytic cells in this 
tumor in combination with the remarkably high accumulation of dendrimers in TAM may 
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contribute to their retention in glioblastoma. The mechanism of nanoparticle accumulation in 
TAM has previously been investigated using cyclodextrin-based particles and carbon nanotubes. 
It is possible that both invading macrophage/monocytes take up nanoparticles in the circulation 
but also that TAM within glioma take up nanoparticles after they distribute in the tumor 
parenchyma [93]. However, the rapid distribution of dendrimer in the tumor, the rapid 
elimination from the circulation and the low accumulation in the reticuloendothelial system, 
suggest that the dendrimers localize more through the latter mechanism. To clarify, the TAM 
uptake shown by dendrimers is specific to activated cells in the tumor, different from the typical 
systemic macrophage uptake/clearance of larger nanoparticles. Neuroinflammation and TAM 
have important growth promoting and pro-invasive effects in brain tumors. TAM is subjected to 
reprogramming in the tumor microenvironment, leading to an alternate immunosuppressive 
tumorigenic M2 phenotype [99]. Topically administered immunomodulatory which block the 
M2-related phenotype of TAM are being investigated for the treatment of glioblastoma [87, 88]. 
Dendrimer-specific accumulation in TAM with low retention in the reticuloendothelial system 
and rapid clearance from the circulation, suggest that these systematically delivered dendrimers 
are promising candidates for the delivery of anti-glioma therapies targeting TAM. 
 
2.5. Conclusion 
Systemically delivered hydroxyl, generation-4 PAMAM dendrimers rapidly accumulate (~ 
fifteen minutes) and are selectively retained in an in vivo intracranial brain tumor model. The 
dendrimers homogeneously distribute throughout the entire 6 mm solid tumor and peritumoral 
area and gradually accumulate in TAM. This homogeneous distribution is retained for at least 48 
hr indicating that the dendrimers used in this study may be effective vehicles for delivery of 
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chemotherapeutics. Also, the intrinsic targeting of neuroinflammatory cells which play a critical 
role in the aggressive nature of glioblastoma may allow for enhanced delivery of 
immunomodulatory molecules to TAM. This study of the pharmacokinetics and biodistribution 
of dendrimers in an intracranial brain tumor model provides insights for the design and 
engineering of systemically-delivered dendrimer-drug conjugates for improved efficacy, and 
reduced side effects for brain tumors. 
  
            




Figure 2.51 Confocal microscopy images of tumor-inoculated rodent brain following 
systemic administration of D-Cy5. 
(A) Low magnification image of tumor inoculated brain, 15 min following systemic 
administration of D-Cy5. Scale bar: 1 mm. Inset images indicate the homogeneous distribution 
of D-Cy5 in the tumor and the restriction of dendrimer in the blood vessel lumen of the 
contralateral hemisphere. Scale bar: 50 μm (B) High magnification images of the tumor and 
contralateral hemisphere 15 min and 4 hr post I.V. administration. Red: D-Cy5; Green: Iba1+ 
microglia/macrophages. Scale bar: 50 µm. Arrow and dashed line delineate blood vessels. 
            




Figure 2.52 D-Cy5 pharmacokinetics in the brain (tumor, peritumor and contralateral 
hemisphere) of a rodent 9L gliosarcoma model. 
(A) D-Cy5 concentration in brain areas 15 min, 1 hr, 4 hr, 8 hr, 24 hr and 48hr following 
systemic administration. The accumulation is expressed as μg of D-Cy5 per g of tissue. Data 
represents mean ± standard error of the mean (SEM) (B) Exposure of respective brain areas to D-
Cy5 following systemic administration as expressed by the AUC of D-Cy5 concentration at 
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different time points. The AUC at 48 hr demonstrates the statistically significant difference in 
dendrimer accumulation between the tumor and the contralateral hemisphere (p<0.05). (C) 
Fluorescence-microscopy image demonstrating vascular density and D-Cy5 accumulation in 
brain tumor 24 hr post I.V. administration. Red: D-Cy5; Green: GFAP (physiologic astrocytes). 
T: Tumor P: Peritumoral area C: Contralateral area; Scale bar: 1 mm. 
  
            




Figure 2.53. Confocal microscopy imaging of 9L gliosarcoma rodent brains following 
systemic co-administration of D-Cy5 and 70 kDa Dextran-FITC. 
(A-C) Low magnification and (D, E) high magnification images of D-Cy5 and Dextran-FITC 
distribution in the tumor area. Blue: DAPI staining of nuclei indicative of the tumor region; Red: 
D-Cy5; Green: Dextran-FITC. Scale bar: 1 mm (Column A-C) and 50 μm (Column D and E). 
White arrow indicates a blood vessel based on DAPI staining (not shown).  
            




Figure 2.54. Characterization of microglia cells (population and activation status) in a 9L 
gliosarcoma inoculated rodent brain using Imaris software. 
(A) Image-based cell count of the Iba1+ microglia/macrophages population per mm2 area in the 
tumor, ipsilateral hemisphere and contralateral hemisphere; *p<0.05 (B) Image-based 
measurement of microglia cell surface to volume ratio as an indication of activation status and 
phagocytic activity of microglia/macrophages in healthy brain, contralateral hemisphere and 
ipsilateral hemisphere of a tumor inoculated brain and tumor tissue. **p<0.01; Statistical 
analysis is based on 3-5 different slices. 
 
            




Figure 2.55. D-Cy5 cellular uptake analysis 24 hr following systemic administration. 
(A) Image based measurement of Iba-1+ cells, D-Cy5 co-localization with Iba1+ TAM, and D-
Cy5 co-localization with DAPI+ cells. Results are expressed as percent of the total DAPI+ cell 
population. *p<0.05; There is no statistical significance between microglia uptake and cell 
uptake. (B-F) High magnification (40X) fluorescence confocal imaging of different anatomic 
locations of a 9L gliosarcoma inoculated brain. Green: Iba1+ microglia/macrophages, Red: D-
Cy5, Blue: DAPI. Scale bar: 100 μm. Statistical analysis is based on 3-5 different slices. 
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3. DENDRIMER TARGET NEUROINFLAMMATION IN FETUS UPON 
INTRA-AMNIOTIC ADMINISTRATION 
3.1. Introduction 
Cerebral Palsy (CP) is a chronic childhood disorder caused by injury to the developing brain 
that occurs either in utero, during birth or soon after birth [117]. As a result, patients usually 
develop permanent motor, sensory and cognitive deficits [118]. According to the United States 
Centers for Disease Control and Prevention (CDC), the prevalence of CP is 1.5-4 per 1,000 live 
births [119]. In infants born prematurely, 5-10% develop motor disability, and 40-50% develop 
some form of cognitive and/or behavioral disability [120]. Although CP has multiple etiologies 
[121], a major pathological substrate is neuroinflammation mediated by activated 
microglia/astrocytes, leading to periventricular leukomalacia (PVL) [122]. Pro-inflammatory 
activation of microglial cells can result in persistent neuroinflammation, including release of free 
radicals, excitotoxic metabolites, and pro-inflammatory cytokines, leading to diffuse white and 
grey matter injury at foci where conventional therapeutics cannot reach and achieve cellular-
targeting [123]. Therefore, an effective therapeutic agent should cross the blood-brain barrier 
(BBB), achieve rapid transport to reach the cells associated with inflammation and injury, 
attenuate both inflammatory and oxidative stress, and have minimal systemic side effects and 
should avoid uptake into healthy regions of the brain and healthy cells [124]. Our previous 
studies have shown that neutral, hydroxyl-terminated polyamidoamine (PAMAM) dendrimers, 
delivered in the postnatal period either though intravenous (i.v.) or subarachnoid administration, 
can localize in activated microglial cells in animals with neuorinflammation [125, 126]. When 
N-acetyl-L-cysteine (NAC), an antioxidant and anti-inflammatory agent, is covalently 
conjugated to the dendrimer, these dendrimer-NAC (D-NAC) conjugates can efficiently 
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attenuate neuroinflammation and improve motor function in a rabbit model of CP [126]. This 
work suggests that there is a window of opportunity in the perinatal period when treatment of 
neuroinflammation may lead to an improvement in motor function and survival in CP. Treatment 
of the mother in the prenatal period is one such opportunity.  
Advances in early diagnosis of prenatal inflammation and chorioamnionitis that are risk 
factors for CP have opened the possibility for prenatal therapies [127]. However, lack of studies 
on drug efficacies, kinetics of prenatal therapy and relative distribution between the maternal and 
fetal compartments have limited the use of fetal therapies in the perinatal period. To achieve 
prenatal delivery of therapeutics to the fetus, intra-amniotic delivery is one possible 
administration route. Although delivery thorough amniotic fluid is a novel delivery strategy, it 
amounts to oral delivery, since the fetus swallows the dendrimers along with amniotic fluid. 
Recent in vivo studies on oral delivery have shown dendrimers as promising intestinal 
penetration enhancers, drug solubilizers and drug carriers [128]. We also demonstrated in a 
mouse model of intrauterine inflammation and preterm birth that intra-amniotically administrated 
D-OH can be orally taken up by the fetus within a few hours post administration [129]. 
Carboxyl-terminated anionic generation 3.5 PAMAM dendrimers (D-COOH) have been reported 
to achieve better oral bioavailability than their hydroxyl terminated neutral counterparts (D-OH) 
[128, 130, 131], while maintaining a similar biosafety profile to D-OH [132]. In present study, 
both D-OH and D-COOH biodistribution and uptake were investigated via intra-amniotic 
administration in the prenatal period to provide opportunity for dendrimers to be ‘orally’ taken 
up by fetus, in a clinically-relevant rabbit model of CP. The fetal uptake, cellular localization in 
the brain, and the bi-directional transport across the maternal-fetal compartment were 
investigated. 
            




3.2. Materials and Methods 
3.2.1. Materials and reagents 
D-OH and D-COOH (Dendritech). Methanol (HPLC grade, Sigma-Aldrich), Cy5-NHS ester 
(GE Healthcare Life Science), stainless steel beads (Fisher Scientific), Fmoc-1,5-diaminopentane 
hydrobromide (Sigma), TSK gel ODS-80 Ts (250 4.6mm, i.d., 5µm) column (Tosoh Bioscience 
LLC, Japan), 4',6-diamidino-2-phenylindole (Molecular Probes), Goat anti-Iba1 (Abcam), Alexa 
Fluor® 594 Goat Anti-Rabbit IgG (Molecular Probes), Anti-CD31 (Abcam), Anti-Cytokeratin 
13 (Abcam) were purchased. 
3.2.2. Animals   
The experimental procedure is described in Figure 3.1. Laparotomy was conducted on 
pregnant rabbits at gestational day 28 (G28, term pregnancy 31 days) under general anesthesia 
(2-3% isoflurane by mask). Saline containing 6000EU of E. coli endotoxin (Escherichia coli 
serotype O127:B8, Sigma Aldrich) (Endotoxin) or equivalent volume of saline alone (Control) 
was distributed equally (100μL per injection site) and injected along the length of the uterus as 
previously described by us. Immediately after this, 50µL of Cy5 labeled D-OH or Cy5 labeled 
D-COOH (concentration of 12mg/mL) were injected intra-amniotically into each gestational sac 
along the right uterine horn using a 30G needle (IA-Dendrimer). This would result in an 
individual fetal dose of ~20mg/kg assuming a fetal weight of about 30g. This dose was based on 
our previous study of intravenous injection of D-NAC in newborn rabbits, where dendrimer was 
administrated at dose ranging from 5.5mg/kg to 55mg/kg [15]. taking into account that intra-
amniotic injection is somewhat similar to oral administration, since the fetus swallows the 
amniotic fluid. The gestational sacs along the left uterine horn were injected with saline alone 
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and served as internal controls (IA-Saline). As a result, 4 different groups were created in the 
study (as demonstrated in Figure 3.1), namely (1) fetuses with endotoxin treatment and intra-
amniotic (IA) dendrimer injection (Endotoxin, IA-Dendrimer); (2) fetuses with endotoxin 
treatment and intra-amniotic saline injection (Endotoxin, IA-Saline); (3) fetuses with control 
saline (Sham) treatment and intra-amniotic dendrimer injection (Sham, IA-Dendrimer); (4) 
fetuses with control saline treatment and with intra-amniotic saline exposure (Sham, IA-Saline). 
Dendrimer used in these 4 groups were either D-OH-Cy5 or D-COOH-Cy5. Routine closure was 
performed and the dams were recovered in individual cages. Cy5 labeled dendrimer solution 
diffused quickly in the amniotic fluid within 1 to 3sec. No indications of leakage were seen 
during or post injection. Procedures for animal sacrifice were previously described [15].  
3.2.3. Dendrimer extraction procedures 
The method for extraction and quantification of Cy5 labeled dendrimers is described 
elsewhere [16]. Briefly, all tissue samples were defrosted before further processing. Liquid 
samples (serum, urine, amniotic fluid) were diluted 10-fold in PBS and filtered through 0.2µm 
membrane before the measurements. For all tissue samples, 100mg of tissue were carefully 
dissected from each organ. For the intestinal tract, only the small intestine was dissected for 
quantification; for maternal organs, at least three samples per organ were dissected from each 
region to have an accurate representation of dendrimer accumulation. To obtain blood free and 
clear supernatants, samples were centrifuged for 15min at 15000rpm and 4oC using 5424R, 
Eppendorf centrifuge. Supernatants were then analyzed by fluorescence spectroscopy.  
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3.2.4. Fluorescence spectroscopy 
Fluorescence spectra of Cy5 labeled dendrimer extracts were recorded using a Shimadzu 
RF-5301 Spectrofluorometer. Calibration curves for Cy5-labeled dendrimers were constructed 
by recording the fluorescence intensity of Cy5 labeled dendrimers at emission wavelength of 
662nm or 665nm, under the maximum of excitation at 645nm. To maximize the intensity of 
emission, different sets of excitation and emission slit widths were applied for different 
dendrimer concentrations.  
Spectra for each extract were recorded using different sets of excitation and emission slit 
widths, the one with the highest emission intensity was selected for quantification of dendrimer, 
applying a calibration curve obtained at the same conditions. To compensate for 
autofluorescence originating from the tissue matrix, intensities registered for control samples 
obtained from each specimen of non-treated animals were subtracted from the values observed 
for samples acquired from animals injected with Cy5 labeled dendrimers. All calculations were 
performed using Excel. Statistical analysis was performed using a student’s T test. 
3.2.5. Immunohistochemistry study of dendrimer accumulation and distribution 
Fetal brains, fetal small intestine and placenta were fixed with 4% PFA once they were 
harvested, followed by processing with gradient sucrose solutions (10%, 20%, 30%). Processed 
tissues were then cryosectioned with a Leica CM1850 cryostat (Leica Biosystems, USA). For all 
samples, DAPI was used to stain the nucleus. For fetal brain samples, goat anti- ionized calcium-
binding adapter molecule 1 (Anti-Iba1, primary antibody) and donkey anti goat 594 (secondary 
antibody) was then used to stain the microglia/macrophages. Anti-CD31 antibody (primary 
antibody) followed with Donkey anti-mouse 488 (secondary antibody) was used to stain the 
blood vessels. For placenta samples, the placental villous structure was identified based on the 
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staining of syncytiotrophoblast layer using anti-cytokeratin13 antibody (primary antibody) and 
donkey anti-mouse 488 (secondary antibody, Abcam). Images were obtained using Zeiss LSM 
710 Meta Confocal Microscope (Carl Zeiss, USA). 
 
3.3. Results 
3.3.1. Preparation and characterization of Cy5 labeled D-OH and D-COOH dendrimers 
In brief, to prepare Cy5-labeled D-OH and D-COOH, both dendrimers were partially 
functionalized with amines using suitable linker and then reacted with Cy5-NHS ester to form D-
OH-Cy5 and D-COOH-Cy5. To prepare D-OH-Cy5, 6-(Fmoc-amino)caproic acid was 
conjugated to the D-OH using PyBOP as coupling reagent with DIEA in DMF. Fmoc groups was 
then deprotected using piperidine/DMF mixture (2:8) to get ~3-4 free primary amine groups on 
the surface of the dendrimer, followed with labeling using Cy5-NHS in bicarbonate buffer 
(pH=9.1): DMSO (1:1) to get D-OH-Cy5 conjugate. The final conjugates were purified by 
dialyzing against 1 kDa membrane and size exclusion chromatograph (SEC) using Sephadex G-
25 gel. The final products were characterized by proton NMR, HPLC/GPC, and fluorescence 
spectroscopy D-OH-Cy5 conjugate was previously demonstrated to be structurally and 
fluorescently stable in human plasma under 37°C. To prepare D-COOH-Cy5, salt free form of 
carboxylate dendrimer was reacted with N-Fmoc-1,5-diaminopentane hydrobromide using 
PyBOP as coupling reagent to yield the Fmoc-functionalized intermediate. The Fmoc 
deprotection, Cy5-labeling of amine functionalized D-COOH, and the purification of final 
product D-COOH-Cy5 were carried out by following similar procedures as described in D-OH-
Cy5 preparation. The final conjugates were characterized by HPLC and fluorescence 
spectroscopy.  
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 To confirm the preservation of neutral and negative surface charge of D-OH and D-
COOH after partially functionalizing with amines, the size and ζ-potential of D-OH, amine 
functionalized D-OH, D-COOH, and amine functionalized D-COOH were measured using 
dynamic light scattering (DLS) and zeta-seizer, as shown in Table 1. After partially 
functionalizing with surface amines, the physical properties of D-OH and D-COOH were 
maintained, with a slightly increase in size (D-OH: from 4.4 ± 0.2 nm to 4.7 ± 0.3 nm; D-COOH: 
from 3.2 ± 0.4 nm to 3.8 ± 0.2 nm) and surface charge (D-OH: from 4.5 ± 0.6 mV to 6.6 ± 0.2 
mV; D-COOH from -28.6 ± 0.7 to -21.8 ± 0.6). 
3.3.2. D-OH and D-COOH partitioned into fetal systemic circulation and were transported into 
maternal side. 
When compared to intravenous administration, intra-amniotic administration of dendrimers 
provides an opportunity for dendrimers to be exposed to the fetal gastrointestinal track (GI track) 
during the circulation of amniotic fluid within the amniotic sac. Hence, amniotic delivery would 
primarily represent ‘oral delivery’ of dendrimers. Based on this, we began assessing whether D-
OH and D-COOH can pass through the intestinal wall and partition into the fetal systemic 
circulation. As expected, we observed that both D-OH and D-COOH transported across the 
epithelial layer of the intestinal villi and were detected along the inner wall of the intestinal villi 
at 24hours (G29) post administration (Figure 3.2), indicating the partition of both dendrimers 
into the fetal systemic circulation. Surprisingly, the transport of dendrimers from amniotic fluid 
to fetal systemic circulation was rapid. In the biodistribution study performed at G29, the 
presence of dendrimers in major fetal and maternal organs was evaluated and expressed as % 
injected dose per gram of tissue or per milliliter of liquid (%ID/g or mL). Most of the dendrimer 
injected had already transported out of the amniotic fluid, leaving only a limited amount of 
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dendrimer (for D-OH, less than 3%/mL, for D-COOH, less than 0.5%/mL) present in the 
amniotic fluid (Figure 3.3, top row). For dendrimer transported out of the amniotic fluid, it was 
either retained in fetal/maternal tissue or cleared out from maternal systemic circulation. We 
determined that ~20-30% D-OH and ~10% D-COOH were retained in the fetal side (Table 2), 
with most of the dendrimers accumulating in the fetal GI tract, lung and placenta (Figure 3.3, 
bottom row). The high accumulation in the placenta was correlated with the finding that 
significant amount of dendrimer was transported out from the fetal side and accumulated either 
in the maternal side (D-OH, 50-60%, Table 2) or excreted out from the urine (D-COOH, 70-
80%, Table 2). The redistribution of majority of dendrimer from amniotic fluid to both maternal 
and fetal compartments observed at G29, and excretion of the dendrimer in the maternal urine 
indicates that dendrimer transport occurs relatively fast. 
3.3.3. D-OH crossed BBB of endotoxin treated fetus at G29, and showed co-localization in 
microglia, while D-COOH was restricted to the blood vessels in the brain. 
Since amniotic-administrated D-OH and D-COOH can both be orally absorbed by the fetus 
and enter into fetal systemic circulation, we seek to understand whether these dendrimers can 
reach the fetal brain parenchyma and target inflammatory cells. To identify whether these 
dendrimers can accumulate in the brain of an endotoxin-treated, injured fetus, we quantified the 
amount of brain accumulation of D-OH and D-COOH at G29 (24hours post dendrimer 
administration). Both dendrimers had similar extent of total brain accumulation in the endotoxin 
treated fetus at G29, with a slightly higher uptake for D-OH (0.28μg/g of dry tissue) compared to 
D-COOH (0.22μg/g of dry tissue) (Figure 3.4A). However, further investigations using confocal 
microscopy revealed that the brain accumulation in the endotoxin treated fetus showed two 
distinctive distribution patterns between the two dendrimer platforms, attributable to the different 
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surface charges of D-OH and D-COOH. As shown in Figure 3.4B, at G29 (24hours after 
dendrimer administration), has less presence in the blood vessels, the relatively high background 
in the brain parenchyma around blood vessels and less co-localization with anti-CD31 
(endothelial stain) indicated D-OH has already diffused across the BBB, and distributed in the 
brain parenchyma around the periventricular region (PVR). On the contrary, D-COOH was only 
observed to be associated with blood vessels, with limited signal in the brain parenchyma. These 
findings suggest D-OH could cross the impaired BBB in the endotoxin treated fetus and 
distribute within the brain parenchyma to reach target disease-associated cells. 
3.3.4. D-OH and D-COOH did not accumulate in the brain parenchyma of sham fetus. 
There are several studies investigating the integrity of the BBB in the developing rodent 
brain in healthy rabbits, the fetal BBB is thought to be intact prior to birth [133, 134], and is 
more representative of the human BBB. We next sought to evaluate the distribution of both 
dendrimers in a sham fetus (‘healthy’ surgical control) to ensure that the BBB at this age is not 
leaky to dendrimer in ‘healthy’ fetuses. Given that sham fetuses were not exposed to endotoxin 
during their gestation period, their BBB should be intact relative to an endotoxin-treated fetus. 
As a result, although there was D-OH accumulation in the brain of sham fetus (Figure 3.5A), D-
OH was mainly associated with the blood vessels, and was not present in the brain parenchyma 
(Figure 3.5B). In contrast, D-COOH were neither associated with blood vessels nor presented in 
the brain parenchyma. 
3.3.5. D-OH selectively localized in ‘activated’ microglia in different stages of activation. 
We have previously shown that D-OH accumulates in microglia in PND1 kits with CP, 
following systemic administration on PND1 [125, 126]. To determine if similar microglial 
uptake was present at PND1 with intra-amniotic administration of D-OH, we investigated the 
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uptake and presence of D-OH in microglia on PND1 following D-OH amniotic administration on 
G28. We found PND1 (G31) kits with CP had pronounced microglial uptake of D-OH. In this 
rabbit model of CP, a progressive increase in activation of microglial cells has been 
demonstrated after the treatment with endotoxin [135]. Interestingly, the D-OH microglial uptake 
also showed an increasing trend with time from G29 to PND1 (Figure 3.6). At G29, traces of D-
OH signal were observed within microglial cells around the lateral ventricle, while at 
G31/PND1, the D-OH signal in microglial cells in the same region intensified significantly.  Our 
results suggest that the observed increasing D-OH uptake is strongly associated with the 
progressive activation and proliferation of microglial cells in this model. Moreover, a longer 
exposure of the fetus to the dendrimer because of recirculation may increase the amount of 
dendrimer available for uptake by the microglial cells. This data also demonstrates that D-OH 
administered intra-amniotically pre-term remains in microglial cells in the postnatal period. 
3.4. Discussion 
We have previously reported significant motor function improvement upon systemic 
dendrimer-NAC therapy, administered after birth in the rabbit model of CP [126]. However, 
since inflammation in the CNS often develops in utero, the possibility of prenatal therapy could 
potentially prevent the injury at a much earlier stage. In this study, we demonstrate that 
dendrimers, when delivered by intra-amniotic administration in the prenatal period, can be 
absorbed by the fetus, cross the BBB in the fetal brain, and target microglial cells in the presence 
of inflammation. Our studies suggest that (1) dendrimers in the intra-amniotic fluid could be 
absorbed by the fetus and transported across the placental barrier into maternal systemic 
circulation; (2) the surface functionality of dendrimers influences its distribution and 
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accumulation in the brain, and the more neutral D-OH was more effective in localizing in 
activated microglia in the brain when compared to the negatively charged D-COOH dendrimers. 
D-OH, which achieved significant efficacy in our previous postnatal therapy study [126], 
and D-COOH, which have better oral bioavailability [136] were selected for this biodistribution 
study. The surface functionality of dendrimer had an effect on brain accumulation and 
distribution. PAMAM dendrimers with amine surface functionality were not used in this study, 
due to the previously known inability to diffuse in brain tissue [67, 137] and the potential higher 
cellular and systemic toxicity [64, 66, 130] compared to those with neutral (OH) and negative 
(COOH) surface functionalities. In our study, D-OH was more efficient in crossing the BBB and 
localizing in microglial cells following intra-amniotic administration in the endotoxin fetuses. 
This occurs due to a combination of the physiochemical properties of the dendrimer and the host 
characteristics including the presence of neuroinflammation. The damage of the BBB provided a 
chance for dendrimers to extravasate, while the small size (~4.3nm) and neutral surface charge 
enabled D-OH to diffuse within the excellular matrix of the brain parenchyma and reach the 
microglial cells. However, D-COOH was temporarily restricted to the blood vessels at the G29, 
presumably due to the negative charge on the BBB surface [138]. The differences of brain 
accumulation and distribution of D-OH and D-COOH stem from the different zeta-potential of 
these two types of dendrimers, which provided a guideline for the design of intra-amniotic 
delivered dendrimer therapies. A more neutral zeta-potential is recommended when design a 
dendrimer-based conjugates for targeting inflammatory CNS disorders. The amount of 
dendrimers brain accumulation is a direct indication of therapeutic potential of dendrimer-based 
therapy, we therefore compared the brain (endotoxin fetus) accumulation of intra-amniotically 
administrated D-OH (administrated at G28) with that of systemic administrated D-OH 
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(administrated at PDN1) at both 24 hours post administration. We found the amount of D-OH 
accumulation through both administration routes are in the same order (~0.3 μg/g for prenatal 
intra-amniotic administration of 20 mg/kg D-OH, ~0.75 μg/g for postnatal systemic 
administration of 55 mg/kg D-OH). This implied that intra-amniotic route has the potential to 
deliver effective dose of therapeutics to the injured brain of CP kits. The D-OH uptake in the 
endotoxin treated fetus was also associated with the activation of microglial cells. In our 
previous mouse study, we did not observe significant microglial uptake of D-OH within 24 hours 
post injection even D-OH was able to present in the brain parenchyma, likely due to the lack of 
microglial activation during the period of dendrimer exposure [129]. In present study, we saw an 
increase dendrimer uptake with the progression of microglial activation. Specifically, microglial 
uptake at G29 was less than that seen at G31 (PND1), likely because the microglia activation and 
proliferation were ongoing and peak activation has previously been shown to be around G31 
(around 72hours after endotoxin exposure) [139]. With the progression of inflammation in the 
fetal brain, the released cytokines (TNF-α, IL-1β, IL-6) polarize microglial cells into a pro-
inflammatory phenotype [140]. This is associated with overwhelming microglial uptake at G31, 
which proves the positive correlation between dendrimer uptake and microglial activation in this 
model [135]. 
3.5. Conclusion 
In this work, we have determined the mechanism for intra-amniotically administrated 
dendrimers to target neuroinflammation in the fetal brain. Our studies suggest both hydroxyl-
terminated (D-OH) and carboxyl-terminated (D-COOH) generation-4 polyamidoamine 
(PAMAM) dendrimers were absorbed by fetuses. D-OH was more effective in crossing the fetal 
blood-brain barrier, localizing in activated microglia. This study demonstrates intra-amniotically 
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administered D-OH could be an effective drug delivery vehicle for targeting fetal inflammation 
and preventing subsequent neurologic injury associated with chorioamnionitis. 
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Table 3.1. Size, ζ- Potential of dendrimers 
Dendrimer Size ± SEM (nm) ζ-potential ± SEM (mV) 
G4-OH 4.3 ± 0.2 +4.5 ± 0.1 
G4-OH-(NH2)4 4.7 ± 0.3 +6.6 ± 0.2 
G3.5-COOH 3.2 ± 0.4 -28.6 ± 0.7 
G3.5-COOH-(NH2)4 3.8 ± 0.2 -21.8 ± 0.6 
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Figure 3.51. Flow chart demonstrating surgery procedures designed in the experiment. 
Endotoxin or saline was administrated at G28 during the laparotomy, followed with intra-
amniotic administration of dendrimer (Cy5-labeled D-OH or D-COOH) or saline. Animals were 
sacrificed at selected time points (i.e. G29 and G31/PND1 post dendrimer administration). BOX: 
Graphic explanation of 4 groups designed in this study. 
            





Figure 3.52. Immunofluorescence images demonstrate D-OH and D-COOH distribute in 
the small intestine. 
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As shown in both lower magnification (top) and higher magnification images (bottom), at 24 
hours (G29) post administration, dendrimers (D-OH and D-COOH) transported across 
epithelium layer of intestinal villi and presented at the inner side of intestinal villi. 
  
            




Figure 3.53. Biodistribution of dendrimers at 24 hours post intra-amniotic administration. 
D-OH, indicated by solid columns and D-COOH, indicated by shaded columns, endotoxin group 
(red columns) and sham groups (blue columns). Biodistribution is expressed as % injected dose 
per gram of tissue or milliliter of fluid [%ID/g of tissue or mL] (top) and % injected dose per 
whole organ in major fetal organs [%ID/organ] (bottom).  
  
            




Figure 3.54. Dendrimers accumulation and distribution in the brain of endotoxin exposed 
fetuses at 24 hours post intra-amniotic dendrimers administration. 
(A) Whole brain quantification shows both D-OH and D-COOH has similar accumulation in the 
brain of endotoxin exposed fetus. (B) Immunofluorescence study shows completely different 
distribution of D-OH and D-COOH in the brain of endotoxin exposed fetuses. D-OH escapes the 
impaired BBB, distributes in the brain parenchyma around the periventricular region; D-COOH 
is only observed to be restricted to the blood vessels. Red: D-OH or D-COOH; Green: Anti-
CD31 labeled endothelial cells on BBB; Blue: DAPI. 
  
            




Figure 3.5.5. Dendrimers accumulation and distribution in the brain of sham fetuses at 24 
hours post intra-amniotic dendrimers administration. 
(A) Whole brain quantification shows D-OH accumulates higher than D-COOH in the brain of 
sham fetuses. (B) Immunofluorescence study shows different distribution of D-OH and D-
COOH in the brain of sham fetuses. D-OH is mainly restricted to the blood vessels, and is not 
presented in the brain parenchyma, while D-COOH is barely seen. Red: D-OH or D-COOH; 
Green: Anti-CD31 labeled endothelial cells on BBB; Blue: DAPI. 
 
  
            




Figure 3.56. D-OH microglia localization was accompanied with microglial activation. 
Low magnification image (top) showed that at G29, most D-OH distributed around the ventricle 
region, while at PND1, D-OH specifically accumulated at the ventricle horn (pointed out by the 
arrow). Magnification of the ventricle horn (bottom) showed that at G29, hint of microglial 
            
             
74 
 
localization was observed, while at PND1, D-OH was selectively localized within the activated 
microglial cells. Red: D-OH; Green: Anti-Iba1 labeled microglial cells; Blue: DAPI. 
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4. NEUROINFLAMMATION AFFECTS MICROGLIA MIGRATION AND 
INTERACTION WITH DENDRIMERS 
4.1. Introduction 
Microglial cells are the primary resident immune cells in the central nervous system (CNS). 
Their migration dynamics are associated with their functions in the CNS [141, 142, 143]. Under 
physiological conditions, microglia are ramified cells, with highly motile processes to help 
survey and maintain the brain microenvironment around them [144]. In response to any acute 
brain injury or damage, these surveying microglial cells can rapidly transform into an activated 
state and migrate to the injury site [145, 146, 147, 148]. However, in neurodevelopmental 
disorders such as cerebral palsy (CP), where activated microglial cells have been implicated, the 
migration dynamics of microglial cells are not well-understood [149]. Previous studies using 
primary microglial cell cultures have demonstrated that lipopolysaccharide (LPS) suppresses 
microglial migration and process extension, while IL4 and TGF-β promote microglial migration 
and branching [149, 150, 151]. However, microglial migration dynamics in a more representative 
biological environment, such as the brain parenchyma, especially in the presence of pathology, 
have not been adequately explored.  
Microglial cells have the ability to phagocytose stressed or dying neurons and express 
phagocytic receptors on their surface [12]. In neuroinflammatory and neurodegenerative 
disorders, pro-inflammatory microglia become neurotoxic by secreting reactive oxygen species 
and cytokines as a response to various environmental stimuli, causing injury to neurons [152, 
153, 154, 155]. We have previously demonstrated that systemic administration of a 
poly(amidoamine) (PAMAM) dendrimer (~4 nm) results in its selective accumulation in 
activated microglia in the brain of newborn rabbits with CP, but not in healthy, age matched 
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control rabbits. We have also shown that newborn kits with CP had evidence of ongoing 
inflammation and oxidative injury in the brain even on day 5 of life (8 days after the insult). 
When N-acetyl cysteine (NAC), a broad anti-oxidant and anti-inflammatory agent with poor 
brain penetration, was conjugated to dendrimers and administered systemically on day 1 of life 
(3 days after the insult) to rabbit kits with CP, a dramatic improvement in motor function and 
attenuation of neuroinflammation was noted by day 5, and was significantly more effective than 
free drug at a 10 time higher dose[86]. However, since the dendrimers do not cross the intact 
blood brain barrier (BBB) in healthy rabbits, it is unclear what role the ‘activated’ nature of pro-
inflammatory microglial cells play in the dendrimer uptake, as the BBB impairment in this rabbit 
model of CP would allow a greater amount of dendrimer exposure within the brain parenchyma 
to the pro-inflammatory microglial cells. 
To address these questions, and further understand the dynamic functions of microglial cells 
in this in vivo rabbit model of CP, we created an ex vivo organotypic whole hemisphere-brain 
slice culture model, with preservation of the microglia pathology in an in vivo condition. Using 
this platform, we evaluated microglial migration and interactions with dendrimers in brain slices 
obtained from newborn rabbits with CP, and compared to that of healthy control newborn 
rabbits. We found that inflammation led to impairment in the surveillance function of microglial 
cells, as demonstrated by hindered migration of microglial cells in the brain of newborn kits with 
CP compared to healthy control kits. Inflammation also influenced the mechanism of microglia-
dendrimer interactions, with enhanced and more rapid dendrimer uptake by the microglial cells 
in brain slices from kits with CP. A better understanding of the dynamics of microglial migration 
in the presence of inflammation and their interactions with dendrimer nano-devices will provide 
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valuable information for evaluating and designing targeted drug delivery systems that can be 
used to modulate microglial function and interactions. 
 
4.2. Materials and Methods 
4.2.1. Materials and reagents 
Cyanine5 NHS ester-labeled hydroxyl terminated Generation 4.0 Poly(amidoamine) 
(PAMAM) dendrimer (D-Cy5, or referred to as dendrimer in this paper) was synthesized using a 
previously established protocol [95]; Tomato lectin- DyLight 594 (Vector Lab, USA); Goat anti-
Iba1 (Abcam, USA); Donkey anti-goat-Alexa flour 488 (Invitrogen, USA); and 4',6-diamidino-
2-phenylindole (DAPI) (Invitrogen, USA) were purchased and used for the studies;  
4.2.2. Animals 
All animal procedures were in accordance with the Animal Care and Use Committee 
guidelines at Johns Hopkins University and the United States Department of Agriculture, as 
described previously [135, 156]. Timed pregnant New Zealand white rabbits were obtained from 
Robinson Services Inc. (Winston-Salem, NC). Briefly, pregnant rabbits in the endotoxin group 
underwent laparotomy at gestational day 28 (term pregnancy is 31 days) and were injected with 
1 mL of saline containing Escherichia coli endotoxin (~6000EU) (serotype O127: B8, Sigma 
Aldrich) along the length of the uterus. At this dose, the newborn kits have been shown to have 
uniform pro-inflammatory microglial activation in the periventricular region (PVR), along with 
increased expression of TNF-α and display a phenotype of CP with predominantly hindlimb 
hypertonia [86, 156]. The healthy control group included pregnant rabbits that had no surgery or 
intervention. All pregnant dams were induced on the evening of gestational day 30 (G30) to 
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control timing of delivery and kits were used for the experiments on postnatal day 1, 
corresponding to G31. 
4.2.3. Organotypic whole hemisphere-brain slice preparation  
Organotypic whole hemisphere brain slices were prepared based on modifications to 
previously published protocols [145, 157, 158]. Rabbit brain slices (350 μm thick) were prepared 
from neonatal rabbits with CP or from age matched healthy controls. To prepare the brain slices, 
neonatal rabbits were decapitated under aseptic conditions after euthanasia. The brain was 
removed, dissected into two hemispheres, and sectioned immediately into 350 μm thick whole 
hemisphere brain slices using a Mcllwain tissue chopper (TED PELLA, Inc., USA). For each 
hemisphere, 6 consecutive slices at the level of the bregma were carefully separated in the 
dissection medium (3.2g Glucose/ 500ml HBSS, 1% of penicillin), while maintaining the 
structures of whole hemisphere-brain slices intact. The lateral ventricle was clearly visualized in 
all the slices. The separated brain slices were transferred onto 30 mm diameter, sterile, porous 
(0.4 um) transparent and low-protein-binding membrane inserts (Millicell-CM, Millipore) in 6-
well tissue culture plates. Each well was prefilled with 1 mL of culture medium, prepared from 
200 mL MEM, 100 mL HBSS RED, 100 mL Horse Serum, 4 mL Glutamax and 1% penicillin. 
The slices were maintained overnight at 37 °C in a humidified atmosphere with 5% CO2 before 
confocal imaging. For the slice viability studies, new culture medium was replaced every two 
days. 
4.2.4. Evaluation of the viability of brain slices under culture 
The whole hemisphere-brain slice viability was evaluated using LDH assay (Cayman, 
USA), which measures the lactate dehydrogenase (LDH) released into the culture medium from 
degenerating cells in brain slices [159]. Culture supernatants from 3 different CP slices were 
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collected at various time points up to 10 days of incubation and replaced with fresh medium at 
each time point (time points evaluated were 6 h, 19 h, 27 h, day 2, day 3, day 5, day 6, day7, 
day10) and frozen at -80 °C. The dilution of LDH in the supernatant was taken into account in 
the calculation. The percentage of LDH released in each whole hemisphere-brain slice was 
quantified by measuring the fluorescence intensity, subtracting the background in negative 
control (culture medium at 0 h of slice culture) and normalized by the intensity of positive 
control (culture medium collected from brain slices treated with Triton-X 100 for 10 days).   
4.2.5. Time-lapse imaging of microglial migration 
Time-lapse imaging of microglial cell migration in brain slices was carried out using a LSM 
710 inverted fluorescence confocal microscope (Zeiss, USA). In preparation for imaging, whole 
hemisphere-brain slices from neonatal rabbits with CP and their age matched controls were 
carefully removed from the insert after overnight incubation and simultaneously transferred to a 
lysine coated glass-bottom culture dish (MakTek Corp, USA). Control and CP brain slices were 
stained and imaged in pairs simultaneously to maintain the same conditions between groups. To 
stain the microglial cells, brain slices were incubated with 10 μL of Tomato Lectin 594 added to 
1 mL of culture medium for 45 min, and then washed three times with the medium to remove 
unreacted tomato lectin. To fix the slice onto the glass-bottom culture dish, 30-40 μL of matrigel 
were applied around the brain slices and then incubated at 37 °C for 15 min to allow curing. 
Culture medium without phenol red was then added into the glass bottom culture dish such that it 
just covered the brain slices. Time-lapse imaging was carried out in the environmental chamber 
under 37°C and 5% CO2 to allow the brain slices to maintain its normal physiology. Prior to 
imaging, the environmental chamber was pre-equilibrated for 30 min. To decrease the possibility 
of any laser induced injury to the cells and photobleaching to the fluorescence labeled 
            
             
80 
 
dendrimers, a low laser power index of 0.5 was used.  Image quality was maintained by using a 
comparatively larger pinhole size and higher gain number to compensate for the decrease of laser 
power. A 20X tilescan with a Z stack of 2-5 μm interval in the vertical direction was used to 
image a tissue dimension of 1 mm × 1 mm in area and 50-80 μm in thickness, and 50 μm in 
depth at the periventricular region. An average of 40-50 microglial cells were imaged per slice. 
The movie was recorded at a temporal resolution of 15 min for 5.5 - 6 h. Maximum intensity 
projection was applied for the final image process. 
4.2.6. Evaluation of dendrimer uptake by microglial cells 
To evaluate the dendrimer uptake by microglial cells, freshly prepared whole hemisphere-
brain slices from rabbits with CP and age matched healthy controls were incubated with 
dendrimer tagged with Cy5 (D-Cy5) (5 ng in 10 μL of sterile DPBS solution) 4 hours after slices 
were sectioned. The D-Cy5 solution was topically pipetted on the tissue along the medial border 
of the lateral ventricle. This region is typically where microglia are seen in high density in 
newborn rabbits [135, 160]. The slices were then incubated at 37 °C in the presence of 5% CO2 
to allow dendrimer to diffuse though the brain tissue and interact with microglia. Slices were 
collected after 1 h, 4 h and 12 h of treatment. At the end of the treatment, the slices were washed 
with cold DPBS solution (4 °C) to inhibit active mechanisms of cell uptake and to remove excess 
dendrimer that is not taken up intracellularly. Brain slices were then carefully transferred to 4% 
formalin solution and 20% sucrose solution for fixation. Slices were incubated overnight with 
Goat Anti-Iba1 for microglia, followed by donkey anti-goat Alexa flour 488 as secondary and 
DAPI for nuclear staining. The stained brain slices were imaged with a20X lens with 3×3 
tilescan, Z-stack with a thickness of 100 μm. The parameters for Cy5 channel were kept 
consistent throughout all images to make them comparable. 
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4.2.7. MATLAB Analysis of microglia movement 
The recorded cell migration was analyzed using MATLAB software. For each group (CP vs. 
Healthy), 3 slices each obtained from different animals were analyzed. Microglia movement 
rates were obtained by transforming the coordinates of microglia centroids into time-averaged 
mean square displacement (<MSD>), calculated as <MSD(τ)> = [x(t + τ) − x(t)]2 + [y(t + τ) − 
y(t)]2 , where x and y represent the cell coordinates at a given time and τ is the time scale or time 
lag. The acquired <MSD> was analyzed using the diffusion function in a 2D scale <MSD 
(τ)>=4Dτα, where D is the diffusion coefficient, which in our case, is related to the microglial 
cell migration. τ is the time lag and α is the dynamic exponent. When α=1, the diffusion or cell 
movement tends to be Brownian motion. When 0<α<1, the diffusion or cell movement is 
considered to be hindered. When α>1, the diffusion or cell movement is considered to be active 
transport which is governed by other factors, such as chemokine or cytokine sensing.  
4.2.8. Analysis of microglial migration velocity and persistent distance 
The analysis of microglial migration velocity and persistent distance was based on the time-
lapse videos recorded by LSM710 confocal microscopy. The speed of microglial migration was 
determined by tracking microglial cell migration path using image analysis software in 
Metamorph. Information such as coordinates and distance at each time point, was recorded. 
Based on this information, the migration speed and persistent distance were calculated by 
averaging the migration velocity at each migration step. The persistent distance is defined as the 
distance (≥ 10μm) traveled by a microglial cell before it makes a significant change in direction 
(absolute angle between previous direction and new direction <70°) [161]. 
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4.2.9. Imaris analysis of microglial cell surface to volume ratio (S/V) and dendrimer co-
localization 
To evaluate the change in morphology of the microglia in brain slices from CP kits when 
compared to those from age matched healthy control newborns, 3D representations of Anti-Iba1 
stained microglia in fixed whole-hemisphere brain slices were acquired using confocal 
microscopy with 40X magnification, with 3×3 tile scans, extending 10 μm in the Z direction with 
1 μm Z-stacks. To analyze the image, Imaris software was applied and microglial surface to 
volume (S/V) ratio was measured. The function ‘surfaces’ was used, and the microglia from 
different slices (n=3 slices/group from 3 different kits each, for the CP and control groups) were 
analyzed for S/V ratio at the beginning of incubation and 24 h post incubation [150]. 
To study the dendrimer uptake by microglial cells, we used the ‘spot’ function to detect 
microglial cells and dendrimer accumulation. For the detection of dendrimer accumulation, a 
threshold was set, where only dendrimers with signal beyond this threshold were considered 
detectable. The ‘co-localization’ function was used to determine whether cell uptake was present. 
In detail, the estimated diameter chosen was 7 μm, 10 μm, and 10 μm, respectively, and the 
threshold was automatically set for ’Quality’ analysis to 5000, 4000, and 7000, respectively. The 
function ‘co-localize spots’ was used and a 10 μm distance threshold was chosen.  
4.2.10. Statistical Analysis 
Statistical analysis of data was carried out by using student’s t-test. Differences were 
considered statistically significant at p< 0.05. 
 
            




4.3.1. Whole hemisphere brain slice viability and microglial pathology is maintained 
throughout the observation window 
Assessment of LDH activity from the medium has been widely used to quantify cell death in 
primary cell cultures. Similarly, in tissue slice culture, the measurement of LDH efflux into the 
culture medium has been found to be highly correlated with the results of cell death from cell 
counting [162]. To determine the cellular viability of the slices, the LDH levels in the 
supernatant were measured. All microglial studies were conducted and completed within the first 
27 h, during which time there was no increase in LDH levels (Figure 4.1), indicating that there 
was no increase in cell death over time during the observation period. This implies that the tissue 
stability was maintained during this period.  We found that the brain slices maintained good 
viability during the time frame when these experiments were conducted, without an increase in 
LDH release.  
To validate whether the acute study (observation window within 24 h) allowed the 
preservation of in vivo pathology of microglial cells, we evaluated the differences in microglial 
morphology between CP and healthy control kits over time in brain slices by quantifying 
microglial surface area to volume (S/V) ratio (Figure 4.2). Microglial cells in the brain slices 
from healthy control kits demonstrated several extended processes with small cell bodies, while 
microglial cells in the brain slices from CP kits had enlarged cell bodies with several short, 
thickened processes (identified with arrow in Figure 4.2). These morphological variations lead to 
differences in the microglial cell S/V ratio, with S/V close to 1.5 μm-1 in the healthy controls 
and S/V ratio less than 1 μm-1 in the CP kits. At 24 h, the end of our observation window, a 
statistically significant difference in S/V ratio between microglia in the healthy brain slices and 
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CP brain slices can still be observed. This difference was noted despite a generalized decrease in 
the S/V ratio of microglia in both healthy and CP brain slices over time. This decrease over time 
from baseline is probably related to a normal response of the microglia to the shear force 
generated during tissue section. In our in vivo model of CP, we observed a similar difference in 
morphology with decreased branches and larger cell bodies in the microglia in kits with CP 
compared to healthy control kits [86]. 
Specifically, the viability of neonatal brain slice culture platform was evaluated by 
measuring the LDH released in the supernatant during 10 days of incubation time (Figure 4.1). In 
general, cells in the brain slices showed increasing degeneration rate with longer incubation time, 
with ~10% of total LDH released at the beginning of incubation and ~50% at the end of 
incubation (10 days). Although there was ~10-20% LDH release caused by shear force induced 
cell damage during the slicing of the brain prior to incubation, cells in the brain slices quickly 
equilibrated with the ex vivo media culture environment, as indicated by the stable level of LDH 
for the first 24 h of incubation. LDH levels remained stable for 3-5 days of incubation time after 
slicing, indicating no increase in cell death and maintenance of tissue viability during this time 
period which provides an observation window long enough for the studies of cell mobility and 
dendrimer uptake. 
4.3.2. Microglial migration is different in brain slices from CP animals compared to brain 
slices from healthy control animals 
To investigate the influence of inflammation on microglial migration, we used the mean 
square displacement (<MSD>) of individual microglia to quantify the migration in the brain 
slices. We found a higher fraction of ‘active migration’ for microglial cells in the brain slices 
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from healthy control animal slices, and a higher fraction of ‘restrictive migration’ for microglial 
cells in CP, indicating impaired migration of microglia in the CP rabbit brain. 
Throughout the imaging time span of 5.5 h, the average <MSD> for the microglia was 
greater in the control brain slices compared to CP slices. The increased migration was reflected 
in the ‘diffusion coefficient’, which is the intercept of the log plot of the <MSD> vs. time graph 
(Figure 4.3A). The microglial trajectories were individually plotted and migration distance from 
the starting point was measured. Microglia in the control brain slices had a much greater 
migration distance compared to those in the slices from CP rabbit kits (Figure 4.3B). To quantify 
this difference, we classified all microglial migration trajectories as 'active transport' or 
'restrictive transport'. Specifically, the microglial migration trajectories in both groups of slices 
were re-plotted by aligning the starting point of each trajectory at the same origin, and by 
defining the cell migration with displacement greater than 20 μm as active transport while 
displacements less than or equal to 20 μm were considered as restrictive transport (Figure 4.4A). 
Over one-half the microglia in the healthy slices (52%) had an active migration pattern with a 
migration distance more than 20 μm from their starting point; while only 17% of microglial cells 
in the CP brain slices demonstrated active migration, 83% of microglial cells in the CP brain 
slices demonstrating restrictive migration (Figure 4.4B). 
To investigate the difference in microglial migration between the healthy and CP slices, we 
used migration velocity and persistent distance to evaluate migration patterns (Figure 4.5). In 
general, microglial cells had a wide distribution of migration velocities. Microglial cells from 
healthy brain slices had migration velocities ranging from ~0.1 μm/min to 1.5 μm/min. This 
range was wider, and the velocities were higher than those of microglial cells from CP brain 
slices, which had migration velocities ranging from ~0.05 μm/min to ~0.3 μm/min. This resulted 
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in a higher average microglial migration velocity in healthy brain slices (~0.33±0.31 μm/min; 
mean ± SEM) than in CP brain slices (~0.19 ± 0.08 μm/min). Persistent distance is a parameter 
used to measure the interactions of the cell with its matrix regulated by adhesion proteins [161]. 
We adopted this parameter and used it as an indication of impediments encountered by microglia 
during migration. The lower persistent distance demonstrated by the microglial cells from CP 
brain slices compared to healthy slices (population median: 15.22 vs. 30.3 μm) may suggest there 
was a greater hindrance for impaired microglia to migrate. 
4.3.3. Dendrimer uptake is affected by microglial pathology 
We have previously reported that intravenous administration of dendrimers resulted in 
increased accumulation in activated microglia in newborn rabbits with CP, but not in healthy 
controls [86, 95]. A similar differential uptake was found between the microglia in healthy 
control brain slices and in CP brain slices.  
In the brain slices from healthy animals, only 20% of microglial cells had detectable 
dendrimer uptake after 1 h of dendrimer treatment (Figure 4.6A). The uptake remained at the 
same level, without obvious increase in uptake even after 12 h of dendrimer treatment, indicating 
limited interactions between dendrimer and microglial cells in the healthy brain slices. This can 
be observed in Figure 4.6B, where the dendrimer signal barely observed. In brain slices from CP 
kits, dendrimer uptake by microglial cells occurred more rapidly and to a greater extent, with 
50% of microglial cells containing dendrimer after 1 h treatment. Microglial uptake of D-Cy5 
increased 1.6-fold after 4 h of dendrimer treatment, in the brain slices from CP kits, with ~80% 
of total microglial cells containing dendrimer (Figure 4.6A). No obvious increase in the number 
of microglial cells containing dendrimer was observed beyond this time point, suggesting that 
dendrimer uptake by microglial cells peaks around 4 h without substantial increase in uptake 
            
             
87 
 
beyond. This is also depicted in Figure 4.6B, where substantial co-localization of D-Cy5 in 
microglia can be seen by 4 h of treatment in the brain slices from CP kits with relatively less 
cellular co-localization observed in the healthy brain slices even at 12 h (Figure 4.6B). 
 
4.4. Discussion  
In this study, we show that maternal intrauterine endotoxin exposure results in a 
morphological change of the microglia with retraction of the processes, restrictive microglial 
migration, and a more rapid and enhanced dendrimer uptake in the newborn rabbit brain with CP 
when compared to age matched healthy controls. These observations provide insights to why the 
dendrimer-drug conjugates are therapeutically effective, since the dendrimers diffuse more 
rapidly in the brain (and are able to ‘find’ the less mobile activated microglia), while taking 
advantage of their increased ability to engulf/uptake dendrimers. 
In vitro and in vivo models are commonly used to study the morphology, behaviors, and 
functions of microglia. In vitro platforms, including primary cell cultures, allow the extraction of 
high purity microglial cells [163]; however, in vitro methods involve destruction of the primary 
architecture and biological environment of the CNS. The physiology or pathology is well 
maintained in in vivo platforms, but it is experimentally difficult to visualize and monitor the 
biological process in specified anatomical locations, especially for regions deep within the brain 
[164]. On the other hand, the ex vivo organotypic whole hemisphere-brain slice platform 
maintains many aspects of in vivo characteristics, such as the 3D structure of the CNS, making it 
possible for microglial cells to interact with the biological environment around them [145, 165, 
166]. Using organotypic whole hemisphere-brain slices as a platform in this study also allows us 
to access and precisely monitor the cells at a specific anatomical location, i.e. the PVR which is 
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the primary area involved in CP. Since the goal of this study was to evaluate the interactions of 
the dendrimer with microglial cells, while avoiding the biological barriers such as the BBB and 
clearance by other organs, the organotypic whole hemisphere-brain slices were an appropriate ex 
vivo platform. Here, we transferred an in vivo animal model of CP into an ex vivo brain slice 
model of CP. Our results suggest that these differences in microglial morphology between the 
two groups, as observed in our in vivo model, were also maintained in our organotypic slices 
[156]. 
The study of microglial migration is associated with the understanding of microglial 
function in the brain, and how they might be affected differently under acute injury and 
inflammation. In the healthy brain, microglia serve a house keeping function by continually 
surveilling the brain microenvironment, pruning neurons, and clearing accumulated metabolic 
products or deteriorated tissue components in parenchyma [144, 167]. In vivo studies in the adult 
mouse brain have revealed that, to perform these functions, microglial cells are highly dynamic, 
where their processes continuously undergo cycles of de novo formation and withdrawal (on a 
time scale of a few minutes) without obvious movement of their cell somata [144]. However, 
under conditions of acute insult, such as laser-induced neuronal injury or blade induced lesion, 
microglial cells quickly react to these insults and transform into a motile form with increased 
migration [144, 168, 169, 170]. This finding was demonstrated in ex vivo studies in neonatal 
rats/mice organotypic brain slices [145, 171]. The shear force generated during the slicing 
process induces mechanical stimulation. Microglia under normal physiologic condition react to 
this stimuli by quickly transitioning into a motile mode within a time period of a few hours, and 
translocating their cell somata, enabling direct physical contact with many cells within a short 
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period of time, and supporting a tissue surveillance function [145]. This was also demonstrated 
by microglial cells in the brain slices from healthy control animals in our study.  
However, in the presence of inflammation, microglial cells behave differently. Inflammation 
induced by LPS can polarize microglial cells into a pro-inflammatory phenotype [172, 173]. 
Studies in primary microglial cell cultures have found that exposure to LPS led to decreased 
microglial migration. Although the mechanisms are not fully understood, LPS has been shown to 
impair microglial migration by down regulation of the P2Y(12) receptor, which promotes 
microglial migration in response to ATP/ADP release [150, 151]. Similarly, in our slices 
obtained from newborn rabbits with CP, microglial migration decreased, as shown by lower 
<MSD> and reduced migration speed, with a higher population of microglia characterized by 
restrictive migration when compared to the microglia in the healthy brain. This restricted and 
decreased migration would indicate the impairment in the normal surveillance function of the 
microglia. It is possible that this impairment in surveillance function of pro-inflammatory 
microglia may play a role in mediating ongoing, chronic inflammation in 
neuroinflammatory/neurodegenerative disorders [153, 174]. Persistence of cell migration, a 
measure to evaluate the ability to migrate in the same direction without turning, has been used in 
studying cell migration, including for cancer cells [175]. The persistent distance of the cell 
migration trajectory may be regulated by multiple mechanisms, including microtubules, adhesion 
proteins, and chemotactic signals [161, 176, 177, 178]. In this study, it was found that microglia 
demonstrate reduced persistent distance in the presence of inflammation. This may be explained 
in part by increased microglial adhesion to the ECM component laminin, due to the up-
regulation of the membrane protein integrin on microglia when exposed to pro-inflammatory 
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cytokines [179, 180]. Integrin expression is known to regulate the adhesion and migration of 
cells in the CNS [179]. 
In our maternal inflammation-induced rabbit model of CP, we have previously reported an 
increase in the uptake of systemically-administered hydroxyl terminated PAMAM dendrimer 
(dendrimer) by ‘activated’ microglia in the newborn brain of kits with CP, but not in the healthy 
neonatal rabbit brain [86]. In the in vivo model, the impairment of the BBB in the CP animals 
may lead to greater exposure of the microglia to the dendrimer in the brain in these animals. 
However, in the ex vivo model, microglia in the healthy brain slices and the CP animal derived 
brain slices, are exposed to the dendrimer to the same extent, due to direct contact of the 
dendrimer to the slice. The substantially greater and more rapid uptake of dendrimers by 
microglia in the CP rabbits when compared to healthy controls may indicate up-regulation of the 
cellular uptake mechanisms by the microglia in CP kits. This is in spite of some levels of 
‘activation’ in both groups due to the shear forces induced by slicing the brain tissue. Microglial 
cells possess full range of endocytic mechanisms, including receptor-mediated endocytosis, 
macropinocytosis and phagocytosis [181]. Upregulation of any or all of these processes in pro-
inflammatory microglial cells in the CP brain [152] could be responsible for the enhanced 
dendrimer uptake and intrinsic targeting of the dendrimers that can be exploited for targeting 
therapeutics specifically to activated microglia [86, 182, 183, 184, 185]. 
4.5. Conclusions  
We used an ex vivo brain slice platform that maintained the physiology of surveying 
microglial cells and pathology of pro-inflammatory microglial cells from an in vivo model. Our 
results suggested there is a significant decrease in the normal migration and surveillance 
functions of microglia in the presence of neuroinflammation in newborn rabbits with CP. 
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However, these microglia were able to uptake dendrimer more rapidly and to a greater extent 
than normal healthy control microglia. Further studies to define the endocytotic processes that 
are up-regulated in activated pro-inflammatory microglia will help to better understand the 
mechanisms by which the dendrimer is taken up by activated microglia. This will also help in 
designing better nanoparticle platforms to target activated microglia.  
  
            




Figure 4.5.1. LDH release by neonatal rabbit brain slices as an indicator of tissue viability 
during incubation. 
% LDH released in neonatal rabbit brain slices during 10 days of incubation period. The released 
LDH concentration is an indicator of the extent of cell death in the whole brain slices. All 
confocal based experiments were conducted within the observation window. For each time 
points, 3 brain slices from CP kits were used. For statistical analysis, the % of LDH released at 
0.125 h was chose to be the reference. *p<0.05, **p<0.01. 
            




Figure 4.52. Microglial cells morphology is different in CP brain slices and healthy brain 
slices within the observation window. 
(A) Representative morphology of microglia cells from cerebral palsy (CP) brain slices and 
healthy brain slices at 0h and 24 h after incubation; (B) Quantitative study of microglia cell 
morphology from CP brain slices and healthy brain slices 0 h and 24 h after incubation, the 
morphology was characterized by cell surface area to cell volume ratio. *p<0.05 (Data shown as 
Mean ±SEM). Scale bar in the figure: 50 μm. For each group, images were acquired from at least 
3 different brain slices. 
            




Figure 4.53. Microglial migration is impaired in brain slices from CP animals vs. healthy 
animals. 
(A) Microglial cells from cerebral palsy rabbit brain slices (red) had lower <MSD> compared to 
microglial cells from healthy rabbit brain slices (blue). The <MSD> was plotted in a log scale as 
a function of time. (B) Representative trajectories of microglia from cerebral palsy rabbit brain 
slices and healthy rabbit brain slices are shown, *p<0.05. 
  
            




Figure 4.54. Microglia trajectories showed higher percentage of active migrating microglial 
cells in healthy brain slices. 
 (A) Overlay of individual microglial cells trajectories, plotted after aligning their starting 
positions. Cells were tracked over a 6h period. Units are in μm. Restrictive migration was 
defined as microglial cells migrating within 20 μm from their starting point (shaded area); Active 
migration was defined as migration of more than 20 μm from their starting point.  A1: 42 
microglial cells from healthy brain slices; A2: 48 microglial from CP brain slices. (B) The 
quantitative study demonstrated higher ‘active migrating’ microglia population in healthy rabbit 
brain slices. In the brain slices from healthy rabbits, more than half the microglia cells (52.4%) 
showed active migration pattern, while 83.3% of microglia from CP rabbit brain slices showed 
restrictive migration pattern.  
            




Figure 4.55. Microglial cells from CP brains showed lower migration velocity and less 
persistent distance. 
(A) Microglial migration velocity distribution for healthy and CP brain slices. Microglia from 
healthy brain slices showed higher average migration velocity during the observation period, 
especially at high migration velocity range, than the microglia from CP brain slices. (B) 
Persistent distance of microglial migration trajectory is greater in the healthy rabbit brain slices. 
Persistent migration was defined as the length (>10μm) traveled by a microglial cell before it 
makes a significant change in direction (absolute angle between previous direction and new 
direction <70°) *p<0.05 For microglia from healthy brain slice: population median 30.3 μm, 
20% percentile:16.6 μm, 80% percentile: 44.4 μm; For microglia from CP brain slice: population 
median 15.22 μm, 20% percentile:11.6 μm, 80% percentile: 17.9 μm. 
            




Figure 4.5.6. Quantitative study of microglial-dendrimer interactions in CP and healthy 
brain slices. 
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(A) Dendrimer uptake by microglial cells, expressed as percent of Iba1+ cells that co-localize 
with D-Cy5 as a function of time (Mean ± SEM). Red: D-Cy5 uptake in microglia from CP brain 
slices; Blue: D-Cy5 uptake in microglia from healthy brain slices. N=3 slices/group. **p<0.01. 
(B) Confocal image of dendrimer treated brain slices (CP, taken under 40X magnification) at 3 
different time points after D-Cy5 treatment (1h, 4h, 12h), and healthy brain slices after 12 h of 
D-Cy5 treatment. Microglial cells in CP brain slices had greater dendrimer uptake (indicated by 
white arrow) than in healthy slices. The orthographic projection clearly indicated the dendrimer 
uptake by activated microglial cells in the brain slice from CP kit, while the dendrimer was 
barely seen to localize in microglial cells in the brain slice from healthy kit. Blue: DAPI, Green: 
Anti-Iba1 (antibody labelling microglia), Red: D-Cy5. Scale bar: 50 μm.  
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5. SIZE AND SURFACE FUNCTIONALITIES AFFECT DENDRIMERS 
ABILITY TO TARGET CNS DISEASES SYSTEMICALLY 
5.1. Introduction 
Drugs that treat central nervous system (CNS) diseases take more than a year longer to 
develop and are less than half as likely to obtain marketing approval than other drugs (Tufts 
CSDD Impact Report, Nov, 2014). The difficulty in achieving improved outcome for CNS 
diseases stems from the inability to deliver therapeutically relevant doses of the therapeutic to 
diseased cells or regions [186]. The BBB and the brain parenchyma are two major biological 
barriers during this process. The BBB continuously regulate the transport of molecules between 
the CNS and outside. More than 98% percent small molecules and all larger molecules (>500 
Da) are excluded from the CNS by BBB [187]. Under many pathological conditions such as 
neuroinflammation and brain cancer, the integrity of BBB is disrupted, offering opportunities for 
drug molecules to passively diffuse into the CNS. The disruption of BBB varies greatly depends 
on the pathological conditions. Even in the same pathological condition, such as the brain tumor, 
the leakage of BBB is not uniform [188]. In addition to BBB, the brain parenchyma as a 
biological barrier in hindering the drug molecules from reach targeted anatomical location has 
also drawn many attentions recently [157]. The brain extracellular space (ECS) is a conduit, 
where many biomolecules forms network, with upper limit of the pore size to be 64 nm, thus, 
hindering the movement of many molecules [189]. Nanomedicine offers high versatility in their 
sizes, with nanoparticles sizes ranging from one nm to hundreds nm, and therefore, can 
potentially address these two barriers if engineered carefully. Investigating the relationship 
between nanoparticle size and their ability to target CNS disease can help better select and 
design nanomedicine for the treatment of CNS diseases. 
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The movement of nanoparticles in the brain parenchyma is also greatly affected by their 
surface functionalities. Heavily PEGylated nanoparticles with a neutral surface charge tend to 
have better movement in the brain ECS compared with non-PEGylated charged nanoparticles, 
mainly due to neutral surface charge minimized adhesive interactions between nanoparticles 
brain ECS [157]. However, for systemically administrated nanoparticles, the ability to cross the 
blood-brain barrier also plays a major role in determine their ability to target CNS disease. 
Therefore, a better understanding of the influence of nanoparticles surface charge on their brain 
uptake is also needed. 
PAMAM dendrimers possess various sizes that can be precisely controlled by tuning their 
generation, and dense surface functionalities that can be modified or engineered. Therefore, 
PAMAM dendrimers have been used as drug delivery vehicles for the treatment of many CNS 
diseases such CP, brain tumor and ischemia [86, 183, 190]. Previous studies on dendrimers size 
and functionality has been greatly focused on their influence on toxicities. In this study, we used 
a rat model of GBM, and investigated the influence of dendrimer size on their pharmacokinetics 
and ability to target brain tumor. We then used a rabbit model of CP to determine how surface 
functionality of dendrimer affecting their target to neuroinflammation. 
5.2. Materials and Methods 
5.2.1. Tumor inoculation 
Female Fischer 344 rats, weighing 125-175 g each (Harlan Bioproducts, Indiana, IN), were 
housed in standard facilities and given free access to food and water. 9L gliosarcoma intracranial 
implantation was performed as previously described [25]. Briefly, the 9L gliosarcoma (obtained 
from the Brain Tumor Research Center, UCSF, San Francisco, CA) maintained in the flank of 
F344, was surgically excised sectioned into 1 mm3 pieces and placed in sterile 0.9% NaCl 
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solution on ice for intracranial implantation. Rats were anesthetized and a midline scalp incision 
was made to identify the sagittal and coronal sutures. A burr hole was made 3 mm lateral to the 
sagittal suture and 5 mm posterior to the coronal suture. The dura was incised, and using a 
surgical microscope and gentle suction a small cortical area was resected. A tumor piece was 
placed in the resection cavity and the skin was closed using surgical staples. All animals were 
treated in accordance with the policies and guidelines of the Johns Hopkins University Animal 
Care and Use Committee. 
5.2.2. Rabbit model of maternal inflammation induced cerebral palsy 
All animal procedures were approved by the Institutional Animal Care and Use Committee 
of Johns Hopkins University, and are as described previously [160, 191, 192]. Briefly, pregnant 
rabbits in the endotoxin group (n = 10 dams) underwent laparotomy at gestational day 28 (term 
pregnancy 31 days) and were injected with 1 mL of saline containing Escherichia coli endotoxin 
(6200 endotoxin units per site) (serotype O127: B8, Sigma Aldrich) along the length of the 
uterus [160, 192]. At this dose, the newborn kits have been shown to have uniform microglial 
activation in the PVR and display a phenotype of CP with predominantly hindlimb hypertonia 
[160, 191, 192]. The healthy control group (n = 6 dams) included pregnant rabbits that had no 
surgery or intervention. After undergoing laparotomy on G28, dams were given maintenance 
fluids of 60cc normal saline subcutaneous every 12 hours. On the evening of G30, dams were 
induced using 10 mEq/kg oxytocin to control timing of delivery, and the newborn rabbits kits 
were immediately removed and placed in an incubator. All kits were given 1cc normal saline 
subcutaneous, weighed, and hand-fed fresh frozen rabbit milk every 6-8 hours until time of 
euthanasia.  Kits were then injected with dendrimer on postnatal day 1 of life (corresponding to 
G31), and kept in an incubator until time of euthanasia. 
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5.2.3. Dendrimer administration for quantification and immunofluorescence 
For rat model of GBM, animals were injected in tail vein with a 3 mg/300 µL dendrimer-
Cy5 solution. To study the dynamics of dendrimer accumulation in the tumor brain, Cy5-labeled 
dendrimers were injected into tumor inoculated rats when the average tumor size was 6 mm in 
diameter and then animals were sacrificed at fixed time points (15 min, 8 h, 24 h, and 48 h). 
Magnetic resonance imaging was used to measure intracranial tumor size. Blood was drawn 
through cardiac puncture and immediately centrifuged to collect plasma. Brains were harvested 
and flash frozen on dry ice for fluorescence spectroscopy based quantification or placed in 4% 
formalin solution for immunofluorescence. 
For rabbit model of CP, animals were systemically injected with 55mg/kg Cy5-labeled 
dendrimers at Postnatal Day 1 (PND1). Animals were sacrificed at fixed time points (1 h, 4 h, 24 
h). 
5.2.4. Fluorescence spectroscopy 
Fluorescence-based quantification of Cy5-labeled dendrimers followed our previously 
published protocol [95]. Briefly, 100-150 mg of frozen tissue (for rat model of GBM) or ~400 
mg of frozen tissue (for rabbit model of CP) were homogenized in 1 mL of methanol using a 
homogenizer (TissueLyser LT, Giagen) in 2 mL DNA LoBind Eppendorf tubes and 
subsequently sonicated. Suspensions were diluted to 100 mg/mL and centrifuged at 15,000 rpm 
for 15 min at 4 °C. The resulting supernatants were subjected to fluorescence spectroscopy. 
Importantly, prior studies showed that Cy5-labeled dendrimers was stable in plasma, and could 
be recovered from the tissue intact, without appreciable release of the conjugated Cy5 [95]. 
For brain tissue, precise dissection of the tumor was performed and the peritumoral area was 
defined as up to 1 mm away from the tumor dissection plane. In the contralateral hemisphere 100 
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mg of the caudate/putamen with the surrounding white matter area was dissected and used for 
analysis. For plasma samples, a sample of 100 μL of plasma and urine was mixed with 900 μL of 
phosphate buffer (0.1 M) and analyzed by fluorescence spectroscopy.  
Fluorescence spectra of D-Cy5 conjugates and that obtained from tissue extracts were 
recorded using a Shimadzu RF-5301 Spectrofluorophotometer (Kyoto, Japan). Cy5-labeled 
dendrimers calibration curves were constructed, following every experiment, under different slit 
widths using the maximum emission wavelength of 662 nm after recording spectra from 650 nm 
to 720 nm with excitation wavelength of 645 nm. The Cy5-labeled dendrimers concentration was 
measured in methanol or phosphate buffer (0.1 M) in solutions ranging from 1 ng/mL to 100 
µg/mL. The slit width was chosen based on the observed fluorescence level of different sample 
sets. For biological samples with low levels of Cy5-labeled dendrimers (i.e. brain, lung, heart), 
the excitation and emission slit width was set at 10; for biological samples with high levels of 
Cy5-labeled dendrimers, (i.e. urine and kidney) excitation and emission slit width was set at 3. 
For the remaining biological samples, excitation slit width of 5 and emission slit width of 10 
were used. All calibration curves exhibited linearity with R2 ~ 0.99. Fluorescence registered 
from tissue of non Cy5-labeled dendrimers injected healthy and tumor inoculated rats was 
subtracted from the values observed from samples of Cy5-labeled dendrimers injected tissue in 
order to account for tissue autofluorescence. 
Concentration of Cy5-labeled dendrimers in the brain was expressed in μg per g of tissue. 
The concentration of Cy5-labeled dendrimers in the other organs was expressed in percentage 
(%) of injected dose per gram of tissue or % of injected dose per organ. Concentrations of the 
Cy5-labeled dendrimers conjugate in urine and blood were expressed in % of injected dose per 
mL or % of injected dose in total amount of urine or plasma. Total plasma concentration was 
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calculated based on the weight of the animal. The brain and plasma quantification data were 
analyzed to calculate the AUC and the brain to serum ratio. 
5.2.5. Immunofluorescence 
Freshly harvested tissues were fixed in 4% formalin for 24 hr, followed by a gradient of 
sucrose solutions before cryosection. Tissues were then sectioned transversely into 30 μm-thick 
slices using a Leica CM 1905 cryostat. Slices were stained with DAPI (nuclei), rabbit anti-Iba1 
antibody for microglia/macrophages, and goat anti-rabbit 595 secondary antibody. Some slices 
were stained with isolectin for endothelial cell staining. Slices were then imaged using a confocal 
LSM 710 microscope (Carl Zeiss; Hertfordshire, UK). For each slice of tumor-inoculated brains, 
images where acquired for the tumor, tumor border and contralateral hemisphere. For control 
(non-tumor) brains, 1-3 representative images were acquired. Settings were optimized to avoid 
background fluorescence based on non-injected control rat brains. Laser power, pinhole, gain, 
offset and digital gain were selected separately for each magnification and kept constant 
throughout the entire study. 
 
5.3. Results 
5.3.1. Increasing the dendrimer size dramatically increased the brain uptake of dendrimers in 
rat model of GBM. 
To determine the influence of dendrimer sizes on their brain uptake, we used generation 6 
PAMAM dendrimer (hydroxyl terminated) and compared their brain pharmacokinetics under 
three different pathological conditions (brain tumor, neuroinflammation, excitotoxicity) with 
those of generation 4 PAMAM dendrimer (hydroxyl terminated). In the rat model of GBM, the 
accumulation of G4 dendrimers follows the order of tumor>peritumor>contralateral hemisphere. 
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The concentration of G4 dendrimers in the tumor/peritumor peaked at around 8 h post injection, 
and gradually decreased, at 48 h post injection, the concentration and AUC of G4 dendrimers in 
the tumor were around 0.7 μg/g, and 36.3 μg/g/h (Figure 5.1A and B). Similar to G4 dendrimer, 
the accumulation of G6 dendrimers in the tumor bearing brain also demonstrated the order of 
tumor>peritumor>contralateral hemisphere. Nevertheless, the accumulation of G6 dendrimers in 
tumor and peritumor displayed an ascending trend during the assessment period, without 
reaching its accumulation peak. At 48 h, G6 dendrimers concentration in the tumor reached 23.1 
μg/g (Figure 5.1A), and the AUC reached 490.8 μg/g/h, which was more than 100 fold higher 
than G4 dendrimers AUC in the tumor (Figure 5.1B). Moreover, G6 dendrimers showed higher 
tumor targeting ability than G4 dendrimers at all time points, as indicated by the brain to serum 
ratio (Figure 5.1C). To study the dynamics of dendrimer accumulation in the tumor brain, 
dendrimers were injected into tumor inoculated rats when the average tumor size was 6mm in 
diameter and then animals were sacrificed at different time points.   
5.3.2. Increasing the size of dendrimers elongate their systemic circulation and reduce renal 
clearance. 
To investigate the mechanism for increased brain uptake for G6 dendrimers, we then 
compared the biodistribution of G6 dendrimers and G4 dendrimers in serum, major organs such 
as kidney, liver and spleen. We found G6 dendrimers showed higher serum concentration and 
prolonged serum half-life than G4 dendrimers. At 48 h post injection, the serum concentration of 
G6 dendrimer (~22% ID/mL) is 17-fold higher than G4 dendrimer (~1.3% ID/mL) (Figure 
5.2A). Further study of dendrimers distribution in kidney, liver, and spleen revealed that the 
prolonged systemic circulation for G6 dendrimer wer associated with the reduced renal clearance 
for G6 dendrimer (Figure 5.2B). For G4 dendrimer, the dendrimer accumulation in kidney 
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increased overtime, reaching ~30 %ID/g at 48 h post injection. However, the accumulation of G6 
dendrimers started to decrease after 24 h, and the accumulation was significantly lower than G4 
dendrimers (~40-fold less at 48 h post injection). The liver accumulation of G6 dendrimers was 
similar to G4 dendrimers at different time points (varied between 0.2% ID/g - 0.5% ID/g), while 
G6 dendrimers showed similar spleen and liver accumulation, however, this accumulation was 3 
- 5 fold higher than G4 dendrimer accumulation in spleen, possibly due to the increased uptake 
by macrophages in the spleen. 
5.3.3. Increasing the size of dendrimers elongate their systemic circulation and reduce renal 
clearance. 
Next, we sought to determine whether G6 dendrimers preserved the homogeneous 
distribution and targeting to the TAMs in the tumor as G4 dendrimers. In the zoomed out 
confocal images (Figure 5.3A), we found G6 dendrimers had slower excretion rate than G6 
dendrimers. For G4 dendrimer, excretion from the blood vessel to tumor tissue started 
immediately (~15min) after i.v. injection, followed with homogeneously distribution in the 
whole tumor and peritumor region. At 24 hours post injection, G4 dendrimers were cleared out 
from the tumor extracellular space, and only retained in the TAMs (Figure 5.3B). For G6 
dendrimers, the presence of dendrimers in the tumor tissue was not observed immediately after 
administration. The concentration of G6 dendrimers gradually increased in the whole observation 
period, while also maintained the homogeneous distribution throughout the whole tumor and 
peritumor region. At 48 hours post administration, G6 dendrimers showed highest concentration 
in the tumor and peritumor area, which is inconsistent with the earlier quantitative study (Figure 
5.3A).  
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Dendrimers ability to target TAMs was also preserved, given the size increase. For G4 
dendrimers, the TAMs uptake happened immediately (~15min) after i.v. injection, while G6 
dendrimers were not presented at this time point, probably due to their slower excretion rate. At 
8 hours, G4 dendrimers not only presented in TAMs but also scattered within the tumor 
parenchyma, which gradually cleared out at 24 hours. G6 dendrimers were mostly taken up by 
TAMs at 8 hours, but the accumulation in the tumor parenchyma also kept on increasing till 24 
hours.  At 48 hours post injection, both G4 and G6 dendrimers were mostly retained in the cells. 
5.3.4. Dendrimers uptake as a function of surface functionality 
In addition to the sizes, we also investigated the dendrimers uptake as a function of 
dendrimers surface functionality. Specifically, we studied the brain uptake of G4-OH (neutral), 
G4-COOH (anionic), and G4-NH2 (cationic) in the rabbit model of CP (Figure 5.4). These three 
dendrimers have approximately the same size and molecular weight, but different surface 
functionalities and zeta potentials at physiological pH (Table 2). We measured total amount of 
dendrimer in the brain (μg) over the total amount of brain tissue analyzed (g tissue). In general, 
all dendrimers demonstrated higher uptake in the brain of CP kits than those of healthy control 
kits (>10-fold overall uptake in the brain of CP kits). We showed the peak accumulation for all 
dendrimers appeared at 4 hours post injection, following with a decrease in total amount in the 
brain by 24h. G4-NH2 demonstrated the highest brain uptake of all dendrimer kinds, and had a 
3-fold higher concentration than other dendrimers. G4-OH and G4-COOH had similar amounts 
in the brain at all time-points. 
5.4. Discussion 
The tumor uptake of nanoparticles is governed by the nanoparticles ability to circulation in 
the blood and their ability to extravasate from the leaky blood vessels and to diffuse in the tumor 
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parenchyma [193]. Many inflammatory diseases share the similar requirements [194]. The size 
of nanoparticles plays a pivotal role in determining these abilities. Nanoparticles need to be large 
enough to achieve enough circulation time to provide exposure to the foci, but also need to be 
small enough so that it can cross the leaky blood vessel, diffuse in in the tissue and eventually 
target the pathology. Due to the existence of BBB, CNS diseases usually have higher 
requirements on the size of nanoparticles. Passive diffusion through the leaky BBTB 
fenestrations has only been demonstrated with molecules smaller than 20 nm [79, 80, 81, 82] and 
unhindered diffusion through the BBTB has been achieved with molecules of 7 nm. In this study, 
the small increase of diameter (from 4.3 nm to 6.7 nm, Table 1) lightly delayed the extravasation 
time of dendrimer into the brain tumor, but did not sacrifice the ability of dendrimers to 
homogenously distribute throughout the whole tumor, and target TAMs. Previous study 
predicted the cutoff size of renal clearance for hydroxyl terminated PAMAM dendrimers to be 6 
nm [195], slightly smaller than the hydrodynamic diameter of G6 dendrimer. Therefore, we 
observed a significant reduction (40-fold) on the kidney accumulation when using G6 
dendrimers. However, the reticuloendothelial system was not activated by this small increase in 
size. Therefore, we did not see a dramatic increase in liver and spleen uptake. As a result, we 
observed prolonged systemic circulation in G6 dendrimers.  
In addition to the rat model of GBM, we also observed the increased uptake at the 
pathological region in the brain among rabbit model of CP and canine model of hypothermic 
circulatory arrest (HCA) (data not shown). 
We also observed the surface functionality can greatly affect the brain uptake of dendrimers. 
Cationic dendrimers G4-NH2 showed highest brain uptake and accumulation. However, 
following studies on the brain distribution of G4-NH2 showed most of them were attached to the 
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BBB, and were not presented in the brain parenchyma or pathological cells (data not shown). In 
addition, cationic PAMAM dendrimers was also found to be toxic to the CNS in many studies. A 
single intranasal dose of G4-NH2 (3 or 15 μg/mouse) can cause alterations of genes expression 
related to the normal brain [196]. In vitro study also showed microgram level of G5-NH2 can 
induce autophagy due to increased intracellular reactive oxygen species generation [197]. 
5.5. Conclusion 
In this study, we used rat model of GBM and rabbit model of CP to study the influence of 
size and surface functionality on dendrimers ability to target CNS diseases. We have 
demonstrated (1) slightly increase the dendrimer generation from G4 to G6 (~2.4 nm increase in 
hydrodynamic diameter) significantly increased the brain uptake of dendrimer in the tumor 
bearing brain, and changed their biodistribution (longer systemic circulation, lower kidney 
uptake), yet this pharmacokinetic improvement did not sacrifice dendrimers ability of 
homogenously distribute in the brain tumor, or target TAMs. (2) Surface functionality influence 
the dendrimer uptake in the brain of CP kits, with G4-NH2 showed ~3-fold higher uptake in the 
brain than G4-OH and G4-COOH. 
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Table 5.51. Characterization of molecular weight, terminal functional groups, size and ζ-








G4 14279 Da 64 4.3 ±  0.2  nm 4.5 ± 0.1 mV 
G6 58304 Da 256 6.7  ±  0.6  nm 0.25 ± 0.4 mV 
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Table 5.52. Physical properties of G4 PAMAM dendrimer with different surface 
functionality. 





± SEM (mV) 
G4-OH Neutral 14.1 4.3 ± 0.2 +4.5 ± 0.1 
G4-NH2 Cationic 14.1 3.9 ± 0.3 +19.5 ± 0.1 
G4-COOH Anionic 11.1 3.2 ± 0.4 -12.2 ± 0.2 
 
  
            




Figure 5.51. Pharmacokinetics of G6 and G4 dendrimers in the tumor bearing brain. 
(A) The compare of accumulation (μg of dendrimer / g of brain tissue) between G6 and G4 
dendrimers in a tumor bearing brain as a function of time. The accumulation of G4 dendrimers in 
the tumor/peritumor peaked around 8 hours post injection, and gradually decreased, while G6 
dendrimers concentration in tumor/peritumor continuously increased. (B) The area under curve 
(AUC) plot also demonstrated G6 dendrimers had around 100-fold higher brain tumor exposure 
than G6 dendrimers within 48 hours; (C) G6 dendrimers showed higher brain to serum ratio, 
indicating better tumor-targeting ability than G4 dendrimers. 
  
            




Figure 5.52. The G4 (green) and G6 (red) dendrimers concentration in serum and major 
organs: kidney, liver, spleen as a function of time. 
(A)  G6 dendrimers showed higher serum concentration and prolonged serum half-life than G4 
dendrimers, which contributed to the higher tumor accumulation and targeting of G6 dendrimers. 
The dendrimer concentration was demonstrated as percentage of total injected dose per milliliter 
of serum; (B) For G4 dendrimers, kidney had most dendrimer accumulation (20%-30%), 
significantly higher than dendrimer accumulation in liver and spleen (~0.3%) at different time 
points.  For G6 dendrimers, the increase of size greatly decreased the renal filtration (as seen in 
(A)) and kidney accumulation. The kidney concentration of G6 dendrimers was much less than 
G4 dendrimers, and started to showed the evidence of clearance from kidney starting from 48 
hours. The liver accumulation of G6 dendrimers was similar to G4 dendrimers, while spleen 
showed ~5-fold higher accumulation, possibly due to the increased uptake by macrophages.  
            




Figure 5.53. The distribution of G4 and G6 dendrimers in the tumor bearing brain as a 
function of time. 
G4 dendrimers had a faster excretion rate than G6 dendrimers. For G4 dendrimer, excretion from 
the blood vessel to tumor tissue started immediately (~15 min) after i.v. injection, followed with 
clearance from tumor after 8 hours. After 24 h post injection, G4 dendrimers were retained in the 
cells. For G6 dendrimers, the presence of dendrimers in the tumor tissue was not observed 
immediately after administration. The concentration of G6 dendrimers gradually increased in the 
whole observation period. At 48 hours post administration, G6 dendrimers showed highest 
concentration in the tumor and peritumor area. Nuclei was stained by 4',6-diamidino-2-
phenylindole (DAPI) (Blue in nuclei panel). Scale bar 3000 μm. The dash line stands for the 
outline of axial sectioned brain.  
            




Figure 5.5.4. The accumulation of dendrimers in the brain of CP rabbit as a function of 
surface functionality. 
All dendrimers demonstrated higher uptake in the brain of CP kits than those of healthy control 
kits (>10-fold overall uptake in the brain of CP kits). We showed the peak accumulation for all 
dendrimers appeared at 4 hours post injection, following with a decrease in total amount in the 
brain by 24h. G4-NH2 demonstrated the highest brain uptake of all dendrimer kinds, and had a 
3-fold higher concentration than other dendrimers. G4-OH and G4-COOH had similar amounts 
in the brain at all time-points.  
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6. DENDRIMER DELIVERY IMPROVE THE EFFICACY OF GCPII 
INHIBITOR AGAINST EXCITOTOXICITY AND ATTENUATE 
NEUROINFLAMMATION 
6.1. Introduction 
Excitotoxicity and neuroinflammation are usually considered as the common hall marks of 
many neurodegeneration disorders [198]. Recent studies have shown mechanistic evidences that 
excitotoxicity and neuroinflammation could be linked to each other through the alterations in the 
glial function in many neuroglial disorders [198]. In neuroinflammation, the activated glial cells 
release inflammatory mediators, and increase oxidative and nitrosative stress, which could 
compromise neuronal survival, and may lead to neuronal dysfunction and degeneration [199]. 
Glutamate excitotoxicity (usually refers to the injury and death of neurons arising from 
prolonged exposure to extracellular glutamate), has been gaining acceptance as a pivotal player 
in neurodegenerative disease [200]. Growing evidences also showed the mechanism between the 
disruption of glutamate regulation and glial activation [201]. Moreover, effects of 
neuroinflammation such as generation of free radicals, mitochondrial dysfunction can directly 
lead to secondary excitotoxicity [198, 200], indicating the central role of excitotoxicity in 
neurodegeneration disorders. 
Human glutamate carboxypeptidase II (GCPII) (EC 3.4.17.21) is implicated in diverse 
pathologies. GCPII cleave N-acetylaspartylglutamate (NAAG) into N-acetylaspartate (NAA) and 
glutamate. NAAG is an abundant peptide in the brain and functions as a selective agonist at 
metabotropic glutamate receptor subtype 3 (mGluR3), which is located on both neurons and 
astrocytes. NAAG could play a significant role in modulating glutamate excitotoxicity. The 
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inhibition of GCPII will decrease the cleavage of NAAG into NAA and glutamate, which 
diminish the secondary source of synaptic glutamate. The increased NAAG can reduce excessive 
glutamate release by activation of presynaptic mGluR3 autoreceptors. The activation of mGluR3 
on astrocytes increases the expression of glutamate transporters, which facilitate the clearance of 
excess glutamate from the synapse. Moreover, decreased NAA can reduce NAA-Na+ co-
transport and subsequent astrocyte Na+ overload and astrocyte pathology. Thus, inhibition of 
GCPII represents a novel strategy for reducing glutamate excitotoxicity.  
The pharmacological inhibition of GCPII activity has exhibited beneficial effects in various 
neurological disorders including stroke, amyotrophic lateral sclerosis, inflammatory and 
neuropathic pain, and traumatic brain injury [202, 203, 204]. Small-molecule ligands targeting 
GCPII are used in diagnostic and treatment in prostate cancer (PCa) and various neurological 
disorders [205, 206]. 2-(3-mercaptopropyl) pentanedioic acid (2-MPPA) is the first GCPII 
inhibitor subjected to clinical patient trials. However, no additional studies were carried out 
because of the relatively low potency of 2-MPPA (estimated human therapeutic dose of ~750 
mgs) together with concerns over potential immune reactivity common to thiol containing drugs 
[205]. Therefore, the development of novel GCPII-specific ligands attracts more attention from 
both academia and industry. 
Nanotechnology is emerging as a promising approach for the treatment of glutamate 
mediated excitotoxicity. Fullerenol (water-soluble derivatives of fullerenes) by itself served as 
ROS scavenger [207, 208] and glutamate receptor antagonist [209], therefore, exerted 
neuroprotective effects against glutamate mediated excitotoxicity. When loaded with estradiol, 
poly(lactic-co-glycolic acid) (PLGA) nanoparticles was found to be more effective than free 
estradiol in reducing glutamate-induced excitotoxic neuronal death [210].  
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Recently, polyamidoamine (PAMAM) dendrimers-based therapies have been applied in the 
treatment of diseases involving excitotoxicity and neuroinflammation [84, 156, 190]. The small 
sizes, high density of surface functional groups, and flexible architecture made PAMAM 
dendrimers extremely useful for delivering drugs to the CNS [59, 211, 212]. More importantly, 
the intrinsic property of targeting to the pathological cells under different pathological condition 
made PAMAM dendrimers more desirable tools for CNS drug delivery. In a canine model of 
hypothermic circulatory arrest (HCA), G4-OH was found to selectively localize in the injured 
neurons. When conjugated with valproic acid (VPA) and n-acetylcysteine (NAC), this 
combination therapy successfully addressed the CNS excitotoxicity and improved the 
neurological deficit score improvements [84] at a 10-fold (compared with VPA) and 30-fold 
(compared with NAC) lower dose. In a mice model of ischemia, dendrimer predominately 
localized in the astrocytes at the initial stage of ischemia induced injury, and subsequently 
shifted to the microglia when the injury progressed to later stage [190].  
In the same cerebral palsy model, we have previously shown D-NAC therapy reduce 
neuronal death and neurodegeneration through attenuating neuroinflammation, specifically by 
targeting activated microglia and astrocytes, and reducing the oxidative stress in the CNS [86]. 
Since reducing glutamate mediated excitotoxicity provided a more direct pathway in mitigating 
neurodegeneration and neuronal death, we hypnotize that using GCPII inhibitor to address 
excitotoxicity in the rabbit model of CP can benefit the disease outcome. In this study, we 
conjugated a GCPII inhibitor to PAMAM dendrimer, and evaluated the conjugates ability to 
inhibit glutamate excitotoxicity and to attenuate neuroinflammation. 
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6.2. Materials and Methods 
6.2.1. Materials and reagents 
G4-OH was purchased from Dendritech (MI, USA); Sephadex G25, Cy5 NHS ester were 
purchased from GE Healthcare (Little Chalfont, United Kingdom); PyBOP, DIEA, Fmoc-
glycine, 2MPPA, DMF, Piperidine, SPDP, TEA, Cyanine 5 (Cy5) NHS Ester, glutathione (GSH) 
were purchased from Sigma-Aldrich (MO, USA); dialysis membrane (2 kDa) was purchased 
from Spectrum Labs (CA, USA). 
6.2.2. Synthesis of Bifunctional PAMAM G4-OH dendrimer having Fmoc-protected amine 
(Intermediate 1) 
The Fmoc-Gly-OH (142.0mg, 0.42mmole) was dissolved into DMF (5mL), PyBOP 
(327.0mg, 0.63mmole) in DMF (5mL) and DIEA (81.4mg, 0.63mmole) in DMF (5mL) were 
added under N2 atmosphere. The reaction mixture was stirred for 45min under room 
temperature. Then, PAMAM G4-OH (200mg, 0.014mmole) was dissolved in DMF (5mL) and 
added. The reaction mixture was stirred for 24hrs under room temperature. Additional PyBOP 
(115.0mg, 0.315mmole) and DIEA (42.0mg, 0.315mmole) in DMF (5mL) were added and this 
reaction mixture was kept on stirring for another 12hrs. The crude product was collected and 
dialyzed against DMF for 24hrs (membrane MW cutoff 1000 Da). Then mixture was evaporated 
in reduced pressure and subjected to high vacuum overnight to get the white floppy semi-solid. 
The semi-solid was then reconstituted with water and lyophilized for 24hrs to get white powder 
form products. 
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6.2.3. Deprotection of Fmoc group (Intermediate 2a) 
The intermediate 1 (250 mg, 0.0149 mmol) was dissolved in anhydrous DMF (10 mL), and 
piperidine/DMF mix solution was added under nitrogen atmosphere to make a mixture of 
piperidine/DMF of 2:8. The reaction mixture was stirred for 30min at room temperature, and all 
piperidine/DMF mixture was evaporated under reduced pressure at 30oC. The crude product was 
dissolved in 15mL DMF and subjected to dialysis with DMF (membrane MW cutoff 1000 Da) 
for 8hrs. The solvent was evaporated under reduced pressure and subjected to high vacuum 
overnight, resulting in a white floppy material 2 (205mg, 91% yield). According to NMR, 
intermediate 2 has 13 free amine group. 
6.2.4. Synthesis of Cyanine5 (Cy5) NHS ester labeled bifunctional dendrimer (Intermediate 2b) 
The intermediate 2a (200mg, 0.013504mmole) was dissolved in bicarbonate buffer (pH=9.1) 
under ice bath and stirred for 10min to allow temperature to decrease, Cy5 NHS (12.7mg, 
0.016035mmole) was dissolved in DMSO (1mL) and added dropwise into bifunctional 
dendrimer solution to allow Cy5 NHS ester to react with the surface amine on bifunctional 
dendrimer for overnight. The reaction mixture was dialyzed against deionized water for 
overnight and was further purified by Sephadex G25 column to remove unreacted Cy5 NHS 
ester, resulting in intermediate 2b. 
6.2.5. Synthesis of SPDP modified bifunctional dendrimer (Intermediate 3) 
The intermediate 2a or 2b (200mg, 0.013504mmole) was reacted with the heterobifunctional 
cross-linker N-succinimidyl-3-(2-pyridyldithio)-propionate (SPDP) (84.375mg, 0.27009) under 
nitrogen atmosphere protection in 20mL DMF and 47μL TEA for overnight. Extensive dialysis 
was conducted to remove the excess SPDP and byproducts to yield intermediate 3. 
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6.2.6. Synthesis of G4-OH PAMAM dendrimer-2MPPA conjugates (D-MPPA) 
To synthesis D-MPPA, intermediate 3 (200mg, 0.013504mmole) was reacted with 2-MPPA 
(57mg, 0.2763mmole) under nitrogen atmosphere protection in 20mL DMSO for 6 hours, 
following with dialysis against DMF for 24 hours with changing of dialysis solvent every 8 
hours to remove excess 2MPPA and byproducts. NMR chromatogram shows around 9 molecules 
of 2-MPPA were conjugated per 1 dendrimer.  
6.2.7. Preparation of Dendrimer-2MPPA and Dendrimer-2MPPA-Cy5 conjugates 
The synthetic strategies for D-2MPPA were aimed to conjugate 2MPPA to G4-OH with a 
linker that can induce triggered release. The molecular structure of 2MPPA possesses three 
functional groups: two hydroxyl groups and a thiol group. Disulfide bond has been engaged in 
many bio-conjugation designs. It has demonstrated stability during circulation and other 
extracellular environment, yet, enabled glutathione (GSH) triggered intracellular release through 
thiol-disulfide exchange reaction [213, 214]. We chose the thiol group from 2MPPA molecule as 
the conjugation site, and aiming to conjugate 2MPPA to G4-OH through a disulfide bond. 
Toward this goal, we designed a 4-step synthesis scheme (Figure 7.1A-B). In the first three steps, 
the terminal hydroxyl groups of G4-OH were partially modified into a protected thiol groups, for 
the later formation of disulfide bonds with the thiol groups on 2MPPA molecules. In detail, 
Fmoc-glycine was conjugated to the surface of G4-OH in the presence of a catalytic amount of 
coupling reagent PyBOP and DIEA, to form intermediate 1. The Fmoc groups were then 
deprotected in the piperidine/DMF mix solution (piperidine/DMF = 2/8) under 0˚C for 30 min to 
form the amine-modified bifunctional dendrimer: intermediate 2a. We noticed some conjugated 
Fmoc-glycine were lost in the deprotection step due to the presence of piperidine. This led to 
around 13 surface amines on intermediate 2a. In the next step, the terminal amines of 
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intermediate 2a were further modified into protected thiol groups (intermediate 3a) by reacting 
with SPDP for 6 hours in the presence of TEA. In the last step, excess 2MPPA was added into 
the reaction mixture of intermediate 3a in situ. Reaction was allowed to go for 24 hours at room 
temperature. The final conjugates D-2MPPA were purified through dialysis against DMF 
(membrane MW cutoff 2000 Da), followed with lyophilization to form brown colored powder. 
In order to study the brain distribution of D-2MPPA, we also prepared Cy5 labeled D-
2MPPA (D-2MPPA-Cy5). To make sure the introduction of Cy5 molecule does not change the 
biodistribution of D-2MPPA, we limited the feeding ratio of Cy5 so that only one Cy5 was 
labeled per D-2MPPA molecule. The procedures for D-2MPPA-Cy5 preparation were based on 
the synthesis scheme of D-2MPPA, and were demonstrated in Figure 7.1C. In brief, amine 
terminated bifunctional dendrimer (intermediate 2a) was labeled with one Cy5-NHS molecule in 
the presence of excess TEA for 12 hours to generate intermediate 2b. The unreacted amines on 
intermediate 2b were further modified based on the D-2MPPA synthesis scheme to generate the 
final conjugate D-2MPPA-Cy5, following with purification through dialysis against DMF 
(membrane MW cutoff 2000 Da) and Size Exclusion Chromatography (SEC) using Sephadex G-
25 column. All other conjugates were purified through dialysis against DMF (membrane MW 
cutoff 2000 Da). The intermediate compounds were characterized with 1H-NMR for their 
chemical structure and payload. 
6.2.8. HPLC analysis of D-MPPA conjugates 
The free 2-MPPA and purified dendrimer D-MPPA conjugate was analyzed using Waters 
HPLC instrument equipped with binary pump, photodiode array (PDI) detector, and auto sampler 
interfaced with Empower software. The HPLC chromatogram was monitored at 210 and 205 nm 
simultaneously using PDI detector. The H2O/acetonitrile (ACN) (0.1% w/w TFA) was freshly 
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prepared, filtered, degassed, and used as a mobile phase. Tosho TSK gel reverse phase column 
with 5μm particle size, 25cm length, and 4.6 mm internal diameter was used. A gradient flow 
was used with initial condition of 90:10 (H2O/ACN) and gradually increasing the gradient 
condition of 30:70 (H2O/ACN) till 15min to 50:50 (H2O/ACN) in 30 min and returning to 90:10 
(H2O/ACN) in 40 min with flow rate of 1 mL/min. 
6.2.9. In vitro toxicity study 
 The toxicity of D-2MPPA conjugate was evaluated on murine microglial cells (BV-2) 
passage 19, using MTT cell proliferation assay kit (Molecular probes, Invitrogen, Oregon, USA). 
The toxicity of D-2MPPA was expressed as percentage of cell viability, and was compared with 
G4-OH, which is considered to have low toxicity; and G4-NH2, which is considered to have 
higher toxicity [215]. BV-2 cells were plated in 96 well plates at a concentration of 1.0 × 104 / 
well. Cells were incubated in Dulbecco’s modified Eagle’s medium (DMEM, Life technologies, 
Grand Island, NY) supplemented with 5% heat in activated fetal bovine serum (Hi-FBS, 
Invitrogen Corp., Carlsbad, CA) and 1% antibiotics (penicillin/streptomycin) (Invitrogen Corp., 
Carlsbad, CA). After 24 h incubation at 37 °C, cells were treated with D-2MPPA, G4-OH and 
G4-NH2 at concentration ranging from 0.01 μg/mL to 100 μg/mL for 24 h before assessment.  
6.2.10. Release study of D-MPPA conjugates under intracellular level glutathione (GSH) 
D-MPPA conjugates (9 mg) were dissolved in 6 mL PBS buffer to form a solution of 1.5 
mg/mL D-MPPA. 17.21 mg or 3.5 μg glutathione (GSH) were added into this solution to mimic 
the intracellular (10 mM) or extracellular GSH level, and to initiate the release of 2-MPPA. 
Another release study was done under 1× PBS solution with no GSH exposure. Samples were 
incubated under 37oC and 5% of CO2 and 400μL of solution collected at different time points 
(0min, 15min, 30 min, 45 min, 60 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, day1, day2, day3 and day4), 
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and immediately analyzed with RP-HPLC. For each time points, triplicate samples were 
measured. The release amount of free 2-MPPA was calculated by integrating the area under peak 
correspondent to free 2-MPPA in the HPLC chromatogram of collected sample, and fit this 
number with a calibration curve of free 2-MPPA. 
6.2.11. Primary glia cell extraction and culture 
Cerebral cortices from 1-3 day old New Zealand white rabbits were excised, meninges 
removed, and cortices were suspended in 5mL of 0.05% trypsin for 15min. DMEM media with 
10% FBS and 1% penicillin and streptomycin (Corning Cellgro, Manassas, VA USA) was added 
to stop the trypsin reaction and the cortices were minced and triturated into small pieces to 
separate the cells. To remove debris, the cell suspension was filtered through a 70μm cell 
strainer, followed centrifugation at 1000 rpm for 5 min under 4° C. The pellet was re-suspended 
in DMEM media containing 4.5 g glucose, 1.4 mM L-glutamine (Corning Cellgro, Manassas, 
VA USA), 10% FBS and 1% penicillin and streptomycin. To culture the primary glia cells, cells 
were plated into 175 mL culture flask (Sigma Aldrich, St Louis, MO USA) and incubated at 37 ° 
C and 5% CO2 atmosphere. Media was changed every two days and cells were allowed to reach 
90% confluence (day 9-13). 
6.2.12. Cell treatment and imaging 
To image the binding of D-MPPA to the GCPII receptor on the cell membrane, we reseeded 
glial cells onto 35mm glass bottom culture dish, allowed cells to reach confluence. Cells were 
then treated with 15µg/mL of D-MPPA-Cy5 and 15µg/mL of D-Cy5, followed with fixation at 
1hr, 3 hr and 8hr post dendrimer treatment, with n=3 for each time point. To fix the cells, cells 
were incubated in 4% formalin solution (4oC) for 15min, then processed with 50:50 
acetone/ethanol solution for 1 min to permeablize the cells. Fixed cells were store at 4oC before 
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imaging. For imaging study. Fixed cells were then incubation with Anti-GFAP (XXX) (1:500) 
for 48 h, followed by 5min incubation in DAPI solution (1:1000). Finally, cells were imaged 
under LSM710 Confocal microscope (Carl Zeiss, Hertfordshire, UK). 
Brain slices were prepared based on modifications to previously published protocols [171]. 
In brief, rabbit brain slices were prepared form PND1 rabbit kits with CP. To prepare the brain 
slices, euthanized rabbit kits were decapitated under aseptic conditions. The brain was removed, 
dissected into two hemispheres and sectioned in a coronal direction immediately into 350 μm 
brain slices using Mcllwain tissue chopper (TED PELLA, Inc., USA). For each hemisphere, 6 
consecutive slices at the level of the bregma were carefully separated in the dissection medium 
(3.2g Glucose/500ml HBSS, 1% of penicillin), while maintaining the intact. After separation, 
each brain slice was transferred onto a low-protein-binding membrane inserts (Millicell-CM, 
Millipore) which is fitting in 6-well tissue culture plates. 1 mL of dissection medium was 
prefilled into the well so that membrane is just in contact with the medium, but not submerged by 
the medium. All the brain slices were maintained overnight at 37 °C in a humidified atmosphere 
with 5% CO2 before therapeutic treatment.  
To treat the brain slice with therapeutics, the dissection medium was first replaced with 
artificial cerebrospinal fluid (ACSF), 100 μL stock solution of PBS or 2MPPA or D-2MPPA in 
1X sterile PBS was then applied directly on top of the brain slices to allow all the therapeutics 
gradually diffusing throughout the brain tissue. To evaluate the treatment efficacy, the treatment 
was terminated at 6 hours (short term) or 24 hours (long term) post incubation (Figure 7.3A). 
The culture medium and the brain slices were collected separately. All samples were stored in -
80˚C before evaluation. 
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The glutamate concentration in liquid and tissue samples were assessed using glutamate 
assay kit (Abcam ab83389). Sample preparation and measurement followed the assay protocol. 
To avoid the variations caused by the different extent of injury from each CP kits, we chose an 
internal control from each rabbit kit, i.e. brain tissue that only received 6 hours of PBS treatment, 
and normalized the other samples from the same kits by the internal control. In this way, the 
measured of glutamate levels were normalized number and do not have a unit. The variation of 
glutamate inhibition within the same group was due to the variation of reaction of each slice to 
the same treatment. 
6.2.13. Animal CP model 
Time pregnant New Zealand white rabbits were ordered from Robinson Services Inc. (North 
Carolina, U.S.A.) and arrived at the facility one week before surgery.  All animals were housed 
under ambient conditions (22°C, 50% relative humidity, and a 12-h light/dark cycle), and 
necessary precautions were undertaken throughout the study to minimize pain and stress 
associated with the experimental treatments. Experimental procedures were approved by the 
Johns Hopkins University Animal Care and Use Committee (IACUC). After one week of 
acclimation, the pregnant rabbits underwent laparotomy at gestational day 28 (G-28) and 
received a total of 3,200-6000 EU of LPS (E. coli serotype O127:B8, Sigma Aldrich, St Louis 
MO) injection along the wall of the uterus as previously described [156, 192].  The control group 
did not receive any intervention.  The kits from the control and CP groups were born 
spontaneously on G31 (full term) and kept in incubators with the temperature of ~32-35°C and 
relative humidity of ~60-70%.  
 
            
             
127 
 
6.2.14. Neurobehavior  
Neurobehavioral tests were carried out on PND1 before drug administration by personnel 
blinded to the experiments. Each animal was videotaped for 10 min and scored on a scale of 0–3 
(0, worst; 3, best) for movements of head and limbs on a flat surface as previously described for 
rabbits [216, 217]. The kits were fed with rabbit milk and the suck/swallow and head turn during 
feeding were assessed on a scale of 0–3 (worst-best) [216]. The muscle tone of each limb was 
scaled at 0-4 (0, limb rigid in flexion or extension; 4, no increase in tone).  The composite score 
was scaled at 0-28 (0, most severe; 28, healthiest).  
6.2.15. Immunohistochemistry 
To evaluate the microglia morphology, the rabbits were anesthetized and transcardially 
perfused with PBS, followed by 4% paraformaldehyde (PFA) in PBS. The brains were removed 
and post-fixed in 4% PFA overnight and cryoprotected in graded sucrose solutions. Coronal 
sections (30 µm, 1:6 series) were incubated in 0.3% hydrogen peroxide (H2O2) solution, 
blocked by 3% normal donkey serum in 0.1 M phosphate-buffered saline (PBS). Sections were 
then incubated overnight at 4°C with goat andti-IBA1 (1:500, abcam, MA. U.S.A.) Sections 
were subsequently washed and incubated with biotinylated secondary antibodies (1:250; Vector 
Laboratories, Burlingame, CA) for 4 h at room temperature. Next, the sections were incubated 
for 2 h in avidin–biotin substrate (ABC kit, Vector Laboratories, Burlingame, CA). All sections 
were then incubated for 2 min in 3,3’-diaminobenzidine (DAB) solution (Vector Laboratories). 
Sections were dehydrated in ethanol and Histo-ClearTM II (Fisher Scientific, Pittsburg, PA, 
U.S.A.), and cover-slipped using mounting medium. To evaluate the co-localization of D-
2MPPA-cy5, GCPII and astrocytes or microglia, the sections were incubated overnight at 4°C 
with chicken anti-GFAP (1:250, abcam, MA. U.S.A.)/mouse anti-GCPII (1:200, GeneTex, CA, 
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U.S.A.), or goat anti-IBA1 (1:250, abcam, MA. U.S.A.)/mouse anti-GCPII (1:200, GeneTex, 
CA, U.S.A.). Sections were subsequently washed and incubated with fluorescent secondary 
antibodies (1:250; Life Technologies, MA, U.S.A.) for 2 h at room temperature. Next, the 
sections were incubated with DAPI (1:1000, Invitrogen) for 15 min. After wash, the slides were 
dried and cover slipped with mountain medium (Dako, Carpinteria, CA, USA). Confocal images 
were acquired with Zeiss ZEN LSM 710 (Zeiss, CA, U.S.A.) and processed with ZEN software. 
6.2.16. Pharmacokinetics (PK) study of 2MPPA/D-2MPPA 
The CP kits from the same litter were randomly divided free 2-MPPA and D-2MPPA 
groups. Animals received intravenous (i.v.) administration of free 2-MPPA (20 mg/kg, 200 μl) or 
D-MPPA (containing 20 mg/kg 2-MPPA, 200 μL) on postnatal day 1 (PND1), and sacrificed at 
1, 3, 24 and 48 h post-injection and perfused with PBS.  The plasma and the periventricular 
regions (PVR), including part of the corpus callosum, corona radiata, internal capsule, caudate 
and dorsal hippocampus, were harvested.  2-MPPA levels in the serum and PVR were measured 
using high-performance liquid chromatography with tandem mass spectrometry (LC-MS/MS) as 
previously described [218, 219]. In brief, a 180-μl serum sample (or 160 μL of matrix blank and 
20 μL of stock for standards) was reacted with 10 μL of 100 mM NEM for 30 min along with 
structurally similar internal standard at 5 μg/ml in acetonitrile. The derivatized samples were 
extracted with methanol followed by vortexing and centrifugation at 10,000 rpm for 5 minutes. 
The supernatant (50 μL) was transferred to liquid chromatography vial and a volume of 5 μL 
used for LC-MS/MS. The tissue samples were processed in a manner similar to serum. In brief, 
tissue samples were weighed, followed by addition of phosphate-buffered saline buffer (also 
containing 10 μL of 100 mM NEM), and volume was adjusted to obtain all samples equal per 
gram of tissue. The samples were homogenized, vortexed, and extracted following the same 
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procedure as described for serum. The calibration range was 1 - 4000 ng/ml for 2-MPPA in 
serum and 50–50,000 ng/ml in tissue. Samples were analyzed on an Agilent 1100 HPLC (Agilent 
Technologies, Santa Clara, CA) coupled to API 3000 mass spectrometer (Applied 
Biosystems/MDS Sciex, Toronto, ON, Canada) Derivatized-2-MPPA was separated on a Luna 
C18 (2 mm) 30 × 4.60 mm, 5 μM column (Phenomenex, Torrance, CA). The mobile phase 
consisted of acetonitrile (A), and 0.1% formic acid in Milli-Q water (B). Separation was 
achieved using a gradient run, with 40% (A) going to 90% (A) over a period, maintaining at 90% 
for 3 minutes, and then re-equilibrating over 3 minutes (40% A) at a flow rate of 350 μL/min and 
total run time of 10 minutes. The mass spectrometry instrument was operated in a negative ion 
mode. The multiple reaction monitoring (MRM) transition of derivatized 2-MPPA was 330 > 
205 (Q1/Q3) and for the internal standard, 645.3 > 323.3 with a declustering potential of 40 V, 
entrance potential 10 V, and collision energy of 21 V. The curtain gas, ion-spray voltage, 
temperature, nebulizer gas (GS1), and auxiliary gas (GS2) were set at 8 psi, 5500 V, 350°C, 8 
psi, and 4 psi, respectively, and the interface heater was on. 
6.2.17. Total TGF-β1 ELISA 
The CP kits from the same litter were randomly divided into three groups: PBS, free 2-
MPPA and D-2MPPA. Animals received intravenous (i.v.) administration of free 2-MPPA (20 
mg/kg, 200 μl), D-MPPA (containing 20 mg/kg 2-MPPA, 200 μL) or PBS (200 μL) on postnatal 
day 1 (PND1), sacrificed at 24 and 48 h post-injection and perfused with PBS.  Total protein was 
isolated from the PVR brain tissues using PBS solution (100 mg brain tissue/ 500 μL PBS). 
Protein concentration was determined by using the BCA kit (ThermoFisher Scientific, Waltham, 
MA, USA). The TGF-β1 protein level was measured using LEGEND MAXTM total TGF-β1 
ELISA kit (Biolegend, CA, USA) according to the manufacturer’s instructions. 
            




All data were processed with GraphPad Prism. Data were presented as mean values ± S.D. 




6.3.1. Characterization of Dendrimer-2MPPA and Dendrimer-2MPPA-Cy5 conjugates 
To determine the chemical structure and payload of D-2MPPA and D-2MPPA-Cy5, we 
characterized them with 1H-NMR (Figure 7.2A). In the 1H-NMR spectrum of 2MPPA (Figure 
7.2A, bottom), the proton peaks from 1.48-1.70 ppm represent the 6 protons at 2, 3, 5 position of 
2MPPA molecule. These peaks were found at around the same region (1.50-1.78 ppm) in the 1H-
NMR spectrum of D-2MPPA (Figure 7.2A, top) and D-2MPPA-Cy5. The proton peaks from 
2.17-2.31 ppm and 2.43-2.47 ppm represent the 3 protons at 4, 6 position and 2 protons at 1 
position of 2MPPA molecule (Figure 7.2A, bottom). Due to the formation of disulfide bonds 
between 2MPPA and intermediate 3a and 3b, the chemical environment of these protons have 
changed (Figure 7.1A, top), which lead to the chemical shift of corresponding peaks to 3.20-3.30 
ppm and 2.80-2.88ppm for protons at 1 and 6 position. The peaks for proton at 4 position merged 
with the peaks represent the internal protons of G4-OH. The presence of 2MPPA proton in the 
D-2MPPA, D-2MPPA-Cy5 1H-NMR spectrum and the chemical shift of some 2MPPA protons 
on the spectrum confirmed the successful conjugation of 2MPPA to G4-OH. To determine the 
number of 2MPPA molecules per G4-OH, we integrated the area of peaks corresponding to 
2MPPA protons (peak 2, 3, 5); the area of peaks corresponding to the shifted G4-OH internal 
protons (3.90-4.10 ppm), and compared these areas with the area of peaks related to the amide 
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protons from D-2MPPA and D-2MPPA-Cy5. The payload of D-2MPPA and D-2MPPA-Cy5 
were calculated to be approximately 13.  
To assess the purity of D-2MPPA and D-2MPPA-Cy5 conjugates, we then characterized the 
conjugates with HPLC. We did not observe the presence of free 2MPPA molecules in the 
chromatogram of D-2MPPA (Figure 7.2B left). The modification and conjugation of 2-MPPA 
changed the surface structure of G4-OH, demonstrated by the increased elution time of D-
2MPPA (~15 min) compared with unmodified G4-OH (~12 min). We also noticed that the 
modification broadened the peak shape G4-OH, indicating the modification dispersed the 
payload distribution of D-2MPPA. The labeling of Cy5 molecule to D-2MPPA greatly changed 
the UV spectrum of D-2MPPA, as demonstrated by the presence of characteristic peak of Cy5 at 
650 nm. Nevertheless, the labeling did not significantly vary the distribution and elution of D-
2MPPA (Figure 7.2B right), with only a 0.6 min elution delay and negligible variation of the 
peak shape between D-2MPPA and D-2MPPA-Cy5.  
We have demonstrated the relative small size and neutral ζ-potential of G4-OH play a key 
role in determine its favorable brain distribution and pharmacokinetics [183]. Next, we sought to 
determine whether D-2MPPA conjugates maintained these physical properties of G4-OH. The 
conjugation of each 2MPPA molecule introduces two carboxyl groups to, and consumes one 
hydroxyl group from G4-OH; therefore, we compared the theoretical molecular weight, ζ-
potential and size of D-2MPPA with G4-OH, which possess 64 terminal hydroxyl groups; and 
with G3.5-COOH, which maintain 64 terminal carboxyl groups (Table 1).  After forming D-
2MPPA, the molecular weight of G4-OH increased to 19,017 g/mole, compared with its original 
molecular weight 14,279 g/mole. The size of D-2MPPA also slightly increased for 30% (G4-OH: 
4.4 ± 0.2 nm, D-2MPPA: 5.9±0.6 nm). Interestingly, the introducing of more carboxyl groups to 
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G4-OH did not significantly reduce the ζ-potential of D-2MPPA (G4-OH: 4.5 ± 0.6 mV, D-
2MPPA: 3.4 ± 5.5 mV). The ζ-potential of D-2MPPA is considered as neutral, especially when 
compared with the ζ-potential of G3.5-COOH (-28.6 ± 0.7 mV). 
We then tested the toxicity of D-2MPPA against BV-2 cell lines to make sure the 
modification did not change the low toxicity nature of G4-OH. We chose amine terminated 
generation 4 PAMAM dendrimer (G4-NH2) as positive control in this study due to the relative 
higher toxicity of amine terminated PAMAM dendrimers [64, 220]. D-2MPPA had very similar 
toxicity on BV-2 cells as G4-OH (Figure 7.1C), with the cell availability fluctuating between 
73% - 97% for D-2MPPA and 77% - 107% for G4-OH when tested at a dendrimer concentration 
range of 1 ng/mL to 100 μg/mL. As expected, the positive control G4-NH2 demonstrated higher 
toxicity. When the treatment concentration was increased to 10 μg/mL, the cell availability 
decreased to 2.3%. 
6.3.2. D-2MPPA is stable under physiological condition but release fast under intracellular 
GSH concentration. 
The in vitro release study was designed to evaluate the stability and the triggered release of 
D-2MPPA conjugates. To study the stability of D-2MPPA, we investigated the release of D-
2MPPA under physiologically relevant solutions such as PBS (pH=7.4) and 2 μM GSH solution 
(designed to mimic the extracellular GSH concentration); to study whether D-2MPPA possess 
triggered release property, we tested the conjugate at 10 mM GSH solution (designed to mimic 
the intracellular GSH concentration). We saw D-2MPPA are stable under both PBS (pH=7.4) 
and 2 μM GSH, with only 6.3% and 5.3% of 2MPPA release from D-2MPPA at the end of 
incubation (~100 hours) (Figure 7.2D bottom). However, under 10 mM GSH (intracellular GSH 
concentration), D-2MPPA demonstrated a fast release, with ~50% and ~80% of 2MPPA release 
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within 2 hours and 12 hours of incubation respectively.  In addition, in the HPLC chromatogram 
of collected release sample, the appearance of free 2MPPA and shifting of D-2MPPA due to the 
reduction of payload after 4-hour incubation also confirmed the release of 2MPPA from D-
2MPPA. 
6.3.3. D-2MPPA is more efficient than 2MPPA in inhibiting extracellular glutamate. 
To evaluate the efficacy of D-2MPPA and compare that with 2MPPA, we assessed the 
potency of D-2MPPA in glutamate inhibition, a direct effect of 2MPPA as GCPII inhibitor. The 
glutamate pathway involves both activated neurons and glial cells. Brian slice from CP kits 
contains both cells types and preserved the activities of many biological pathways. In addition, 
since 2MPPA inhibits the production of extracellular glutamate in the CNS, which can be 
separately measured in the culture medium in this ex vivo slice culture system, we chose brain 
slices generated from PND1 CP rabbit kit as a platform for this study. To evaluate the dose 
response, we treated the brain slices with 0.1 µM (for 2MPPA, IC50 = 0.09 µM [221]) and 10 
µM 2MPPA (~100-fold of IC50 dose, 2-fold of D-2MPPA accumulation in the PVR region from 
the CP kits). The positive control received PBS treatment. The slice preparation and treatment 
procedures were described in Figure 7.3A.  
Since the brain slices were generated from the brain of CP rabbit kit, where both 
excitotoxicity and neuroinflammation were presented, an increased total glutamate concentration 
with time was expected. In the PBS treated group (Figure 7.3B), we saw a 5.9-fold increase of 
total glutamate production between 24 hours (4.19 units) and 6 hours (0.72 units).  
In general, D-2MPPA is more effective in inhibiting extracellular glutamate production 
(measured from culture medium) than 2MPPA (Figure 7.3B). Specifically, at 6 hours, 0.1 µg/mL 
of 2-MPPA significantly inhibited the glutamate production for 29% (~0.51 unit) compared with 
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the PBS group (~0.72 unit); increasing the treatment dose to 10 µg/mL did not show better 
inhibitory effect, yet resulted in a slight reduction of glutamate inhibition (18% inhibition 
compared with PBS treated group). D-2MPPA had better inhibition effect (31% inhibition) at 
lower dose than 2MPPA. However, it is worth noting that increasing the D-2MPPA dose for 
100-fold further enhanced the inhibitory effects to 54% inhibition. At 24 hours, newly produced 
extracellular glutamate diffused into the culture medium. A more pronounced inhibition was 
observed as a result of longer incubation time. 2MPPA inhibited glutamate production (2.1units) 
for 50% at lower dose compare to PBS treatment (4.2 units), yet still displayed worse inhibitory 
effect at higher dose (43%). Interestingly, D-2MPPA had better effect than 2MPPA at lower 
dose, with a 60% inhibition of glutamate production at lower dose, but demonstrated a strong 
inhibition at higher dose (81% glutamate inhibition). We also observed that both 2MPPA and D-
2MPPA inhibited the tissue glutamate production, yet the inhibitory effect was not as strong as 
for the extracellular glutamate measured from the culture medium.  
6.3.4. D-2MPPA improve the TGF-β level of LPS treated BV-2 cells 
The inhibition of glutamate production is concomitant with the increase of NAAG in the 
CNS, which further activates mGluR3 and induces the release of TGF-β [222]. This can decrease 
microglial activation and potentially enable conversion of activated microglia to a more anti-
inflammatory phenotype. Therefore, we sought to determine if D-2MPPA can improve the TGF-
β level when microglial cells are activated. BV-2 cells were first treated with 100 ng/mL LPS for 
3 hours to induce activation. We found LPS treatment suppressed the TGF-β expression for 
~50% compared with control group (Figure 7.4). After exposing BV-2 cells to LPS, we then 
applied different doses of D-2MPPA/MPPA to BV-2 cells for 24 hours (i.e. 0.1 μg/mL, 1 μg/mL, 
and 10 μg/mL). BV-2 demonstrated a dose responsive effect to the 2MPPA treatment (Figure 
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7.4), with 20%, 68%, and 160% TGF-β improvement at 0.1 μg/mL, 1.0 μg/mL, and 10.0 μg/mL 
concentration of 2MPPA treatment. Interestingly, treatment of BV-2 cells with 0.1 μg/mL D-
2MPPA dramatically improved the TGF-β level for 140%. This TGF-β enhancement is similar to 
the effect of 10.0 μg/mL 2MPPA treatment (160% enhancement). Even though D-2MPPA did 
not show significant dose response, the TGF-β levels in all D-2MPPA treated groups were close 
or higher than the TGF-β in the control groups, indicating the D-2MPPA enhanced the efficacy 
of 2MPPA. 
6.3.5. Dendrimer promotes the cell-specific 2-MPPA delivery  
To determine whether the dendrimer can deliver the 2MPPA in a cell specific manner, we 
systematically (i.v.) injected the D-2MPPA-cy5 on PND1 in endotoxin kits and analyzed the D-
2MPPA-cy5 distribution in the PVR 24 h post-injection. We found that the D-2MPPA-cy5 is co-
localized with GCPII in both activation microglia and astrocytes in endotoxin kits (Figure 7.4B).  
6.3.6. Dendrimers enhance the brain uptake of 2MPPA 
To determine whether the glial-specific targeting property of D-2MPPA can result in higher 
accumulation of 2-MPPA at the injury site, we intravenously (i.v.) administrated D-2MPPA 
(containing 20mg/kg of 2-MPPA) and 2-MPPA (20 mg/kg) to the CP kits and the healthy control 
kits. The concentration of 2-MPPA at the PVR region and in the serum were analyzed at 1, 3, 24 
and 48 h post-injection (Figure 7.6A). We found that 2-MPPA level in the PVR region of D-
2MPPA CP group at each time point was higher than the effective concentration (IC50 = 90 
nM). The 2-MPPA level in the endotoxin D-2MPPA group peaked at 3 h post-injection (4.3 μM, 
~50 fold of IC50), which was 7.2-fold higher than the endotoxin 2-MPPA group (0.6 μM), 
indicating the dendrimer enhanced the 2MPPA brain penetration. Whereas, this enhanced drug 
accumulation in PVR was not observed in the healthy control kits without injury. In the PVR 
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region of healthy control kits, the concentration of both D-2MPPA and 2MPPA decreased over 
time, and showed very similar level of accumulation at 3 hours (D-2MPPA: 0.9 μM, 2-MPPA: 
0.5 μM) and 24 hours (D-2MPPA: 0.05 μM, 2MPPA: 0.5 μM).  
We further analyzed the serum 2-MPPA level in D-2MMPA and 2-MPPA group to 
determine the association between brain uptake and serum 2-MPPA level.  We found that the 
free 2-MPPA level was similar among all the groups at 1 h post-injection.  The 2-MPPA level in 
the 2-MPPA group in CP kits and the healthy controls (D-2MPPA and 2-MPPA groups) rapidly 
decreased 1 h post-injection (Figure 7.6A), which is consistent with a previous study in a rat 
model of neuropathic pain, in which the free 2-MPPA was rapidly cleared out during the first 
hour after administrated intravenously [218]. However, the free 2-MPPA serum level in the D-
2MPPA CP group kept elevated at 3 h post-injection and higher concentration in the serum at all 
the monitored time points. These results demonstrate that D-2MPPA enhanced the circulation 
time of free drug in the CP kits. Moreover, the higher serum 2-MPPA level may indicate the 
deficiency of clearance in the CP kits.  
6.3.7. The accumulation of 2-MPPA in the PVR correlates with the extent of brain injury 
 To determine the correlation of the 2-MPPA level and the disease phenotype, we plotted the 
PVR 2-MPPA level against the disease phenotype in the CP kits. We found that the 2-MPPA 
brain uptake in the D-2MPPA endotoxin group is closely correlated with the disease phenotype, 
the more severe the disease phenotype, the higher level of the 2-MPPA uptake (Figure 7.6B), 
which may be related to the extent of the blood brain barrier injury.  
6.3.8. D-2MPPA treatment improved the short-term neurobehavior of CP rabbit. 
To evaluate the effect of D-2MPPA on neuroinflammation, we evaluated the short-term 
neurobehavior of healthy control, PBS, MPPA, DMPPA treated group at 0 h and 48 h post 
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treatment (Figure 7.7). The D-2MPPA significantly improved the sucking and swallowing, head 
movement and muscle tone, compared with the PBS or MPPA treated groups.  
 
6.4. Discussion 
Dendrimers could enhance the brain uptake of small molecule drugs, even though this has 
not been proved directly. Our study provided a direct proof that D-2MPPA enhanced the 
accumulation of 2MPPA in the injured brain, by measuring the 2MPPA concentration in the 
PVR region. We found a 7.2-fold increase of 2MPPA uptake enabled by D-2MPPA, when it 
reached its peak concentration in the PVR (Figure 7.6A). This enhanced brain uptake in the CP 
kits was associated with the upgraded serum concentration in the D-2MPPA injected group. The 
dendrimer pharmacokinetics and the pathology of CP both contributed to the increase in the 
2MPPA concentration of the D-2MPPA injected group. PAMAM dendrimers are believed to 
enhance the systemic circulation time of free drug molecules [211]. We showed here D-2MPPA 
increased the serum concentration of 2MPPA in both CP and control kits. Interestingly, we also 
found dendrimer demonstrated a higher concentration in the serum of CP kits, than the serum of 
control kits. But this difference was observed among free 2MPPA injected groups. Renal 
filtration has been identified as the major clearance pathway for hydroxyl terminated G4 
PAMAM dendrimers in many animal models [95, 183]. The increased 2MPPA concentration in 
the D-2MPPA injected CP kits was probably associated with the damaged renal function in these 
kits. However, this also provided a higher opportunity for D-2MPPA to passively diffuse across 
the leaked BBB and entering the brain. 
In the CP kits, the 2MPPA accumulation in the PVR region of D-2MPPA injected group 
demonstrated large variation, which is not observed in the control kits. Therefore, we further 
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phenotyped the uptake of 2MPPA in CP rabbit kits, and demonstrated a positive correlation 
between 2MPPA uptake in the brain and the disease severity was shown in the D-2MPPA 
administrated group, and a lack of correlation of negative correlation was shown in the free 
2MPPA injected group (Figure 7.6B). This finding was probably related to the dendrimers 
property to accumulate and retain in the brain where the BBB is more impaired, and population 
of activated microglial cells are alleviated, indicating the potential to use dendrimer as an 
imaging tool for the assessment of neuroinflammation [211]. The lack of positive correlation in 
the free 2MPPA injected group might limit their application in the treatment of severely injured 
patients in clinics, since 2MPPA demonstrated least accumulation in the severely injured brain. 
However, conjugating 2MPPA to dendrimer solved this problem, and increased the probability in 
the clinical translation of dendrimer-based nanomedicine.  
As a member of GCPII inhibitor, 2MPPA impose its inhibitory effect by forming a complex 
with GCPII receptors, and therefore hindering the interaction of NAAG with GCPII receptors. 
Specifically, the glutarate (pentanedioic acid) portion of the 2MPPA can interact with the C-
terminal glutamate recognition site of GCPII, and the thiol group of 2MPPA can form chelation 
with the active site zinc ion [223], although no study has shown both of these interactions are 
needed to interfere with the normal function of GCPII. In the presence of neuroinflammation, 
dendrimers could intrinsically target activated microglia and astrocytes [86], which have been 
shown to have upgraded expression of GCPII receptors on their cell members [224]. Therefore, 
we hypothesize that when conjugated with 2MPPA, dendrimers have the ability to increase the 
probability of 2MPPA to interact with GCPII by delivering 2MPPA to the GCPII expressing 
cells. In the rabbit model of CP, we successfully identified the expression of GCPII receptors on 
the activated astrocytes and microglial cells in the PVR region of PND1 CP kits. (Figure 4B). 
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We also observed the co-localization of D-2MPPA with LPS activated astrocytes in vitro (Figure 
4A), and localization of D-2MPPA with GCPII receptor expressed on the activated microglia and 
astrocytes. This observation indicated that dendrimers not only increased the brain uptake of 
2MPPA in the CP kits, but also favored the interaction between 2MPPA and GCPII receptor by 
targeted deliver 2MPPA to the GCPII expressing cells. Even when brain slices from CP kits were 
exposed to free 2MPPA and D-2MPPA at the same dose, this cell-specific delivery of 2MPPA 
enabled a better inhibition on extracellular glutamate production.  
Lastly, we showed that targeting glutamate excitotoxicity also helped in attenuating 
neuroinflammation, indicating a new aspect in the treatment of CP. 
 
6.5. Conclusion 
In this study, we have showed that by covalently conjugating a GCPII inhibitor 2MPPA to 
the dendrimers, we could increase the accumulation of 2MPPA in the injured brain of CP kits. 
This accumulation of dendrimer delivered 2MPPA was positively correlated with the disease 
severity. D-2MPPA targeted the activated microglia and astrocytes and co-localized with the 
GCPII receptor expressed on these cells. This dendrimer-based targeted delivery resulted in a 
better effect in inhibiting the extracellular glutamate production in the brain tissue, improving the 
TGF-β level in vitro, and further attenuated the neuroinflammation in vivo, with significant 
clinical applications. 
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Size ± SEM (nm)  ζ-potential ± SEM (mV) 
G4-OH 14,279 4.4 ± 0.2  4.5 ± 0.6 
G3.5-COOH 12,931 3.2±0.4  -28.6 ± 0.7 
D-2MPPA 19,017 5.9±0.6  3.4 ± 5.5 
D-2MPPA-Cy5 19,555 - - 
 
            




Figure 6.5.1. Synthesis scheme of D-2MPPA and Cy5 labeled D-2MPPA (D-2MPPA-Cy5). 
(A) Preparation of amine functionalized bifunctional dendrimer (Intermediate 2a); (B) 
Preparation of Dendrimer-2-MPPA conjugate (D-2MPPA); (C) Preparation of Cy5 labeled 
Dendrimer-2-MPPA conjugate (D-2MPPA-Cy5) 
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Figure 6.52. Characterization of D-2MPPA and D-2MPPA-Cy5. 
(A) 1H-NMR spectra of D-2MPPA (top), and 2MPPA (bottom). The appearance of 2MPPA 
protons (Figure 1A bottom, 1, 2, 3, 5, 6 positons in 2MPPA molecule) in D-2MPPA (Figure 1A 
top); the chemical shift of 2MPPA protons at position 1, 6 and internal protons from G4-OH 
confirmed the success of conjugation; the payload of 2MPPA was calculated to be around 13 
based on integration of 2MPPA protons and compare to integration of amide protons from G4-
OH.  (B) The HPLC chromatogram of G4-OH, D-2MPPA, 2MPPA confirmed the purity and the 
successful conjugation of 2-MPPA to G4-OH. Left: the elution time for 2-MPPA (17.1 min), G4-
OH (12.0 min), and D-2MPPA conjugate (15.0 min) are different from each other. All peaks 
were monitored at λ=212 nm. Right: the elution of D-2MPPA (15.0 min) and D-2MPPA-Cy5 
(15.6 min). The slightly shift of retention time of D-2MPPA-Cy5 indicated the labeling of Cy5-
NHS ester to the D-2MPPA. D-2MPPA-Cy5 was monitored under λ=650 nm. (C) The toxicity of 
G4-OH, D-2MPPA, and G4-NH2 against BV-2 cells lines. D-2MPPA demonstrated low toxicity 
against BV-2 cells as G4-OH, G4-NH2 displayed toxicity against BV-2 cells at a concentration 
of 1 μg/mL. (D) The release profile of D-2MPPA at different in vitro conditions, monitored by 
HPLC at λ=210nm. D-2MPPA is stable under physiological pH (pH=7.4) and extracellular GSH 
concentration (2 μM) during the ~100 hours of incubation time. The release of D-2MPPA is 
triggered by the intracellular concentration of GSH (10 mM), with 50% of 2MPPA released after 
2 hours of incubation. 
            




Figure 6.53. D-2MPPA/2MPPA inhibited glutamate production in ex vivo brain slice 
culture. 
 (A) Ex vivo brain slice culture experiment scheme. The brain slices were treated with different 
doses of PBS/D-2MPPA/2MPPA for 6 hours or 24 hours before the tissue and culture medium 
were collected. (B) The glutamate concentrations measured in the culture medium from each 
group. In ex vivo brain slice culture platform, the culture medium glutamate represents the 
extracellular glutamate. At similar dose, D-2MPPA inhibited extracellular glutamate production 
more efficiently than 2MPPA. The measured glutamate concentrations from all samples were 
normalized by the internal control (glutamate amount in the brain slice at 6 hours post PBS 
treatment). For each group, 4-6 slices from 3 different rabbit kits were measured. 
  
            




Figure 6.54. D-2MPPA enhanced the TGF-β level in LPS treated BV-2 cells. 
Treatment of BV-2 cells with 100 ng/mL LPS for 3 hours suppressed the TGF-β for 50% (black 
bar) compared with the control group (shaded black bar). Gray bars: Treatment of LPS activated 
BV-2 cell with 2MPPA for 24 hours (0.1 μg/mL, 1 μg/mL, and 10 μg/mL) enhanced the TGF-β 
level in a dose responsive manner. Treatment of LPS activated BV-2 cell with D-2MPPA (0.1 
μg/mL, 1 μg/mL, and 10 μg/mL) improved the TGF-β to concentrations that were close to or 
higher than the control group. 
  
            




Figure 6.55. In vitro and in vivo cell localization of D-2MPPA-Cy5 with microglia and 
astrocytes. 
(A) In vitro treatment of D-2MPPA-Cy5 on LPS activated the mixed glial cell culture, D-
2MPPA-Cy5 was shown to co-localize with the activated astrocytes. Red: D-2MPPA-Cy5; 
Green: Anti-GFAP; Blue: DAPI. Scale bar: 50 μm. (B) The in vivo study showed the co-
localization of D-2MPPA-Cy5 with GCPII receptors expressed on the activated microglia and 
astrocytes at 24 h post D-2MPPA administration. Images were taken at the PVR region of the 
brain form CP kits. Green: Anti-GFAP; Red: Anti-GCPII; Purple: D-2MPPA-Cy5; Blue: DAPI. 
  
            




Figure 6.56. The pharmacokinetic analysis of intravenously administrated D-2MPPA and 
2MPPA. 
(A) The accumulation of 2MPPA in the in the PVR region and serum of CP and healthy control 
kits. D-2MPPA demonstrated the highest accumulation in the PVR of CP kits, with a peak 
accumulation at 3 hours (4.2 μM, ~50-fold of IC50 concentration, ~7.2-fold higher than free drug 
accumulation) post injection and gradually cleared out within 48 hours. In the PVR region of 
healthy control kits, the concentration of both 2MPPA and D-2MPPA decreased with time. In the 
serum, the concentration of free drug decreased rapidly within the first hour after administration, 
with 0.3%ID/mL and 1.0%ID/mL of 2MPPA left in the serum. Both D-2MPPA and free 2MPPA 
showed higher concentration in the serum of CP kits compared with those of healthy control. (B) 
For D-2MPPA injected groups, accumulation of 2MPPA in the PVR region of CP kits was 
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positively correlated with the disease severity. 
            




Figure 6.57. D-2MPPA treatment improved the short-term neurobehavior of CP rabbit. 
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Ph.D., Materials Science & Engineering, The Johns Hopkins University, Baltimore, USA  2016 
B.E., Materials Science & Engineering, Donghua University, Shanghai, China 2010 
Honors: Outstanding Student, Top 10 GPA 
II. RESEARCH EXPERIENCE 
2011-current Ph.D. Candidate, Materials Science and Engineering 
Center for Nanomedicine, Johns Hopkins School of Medicine, Baltimore, MD  
Advisor: Rangaramanujam M. Kannan, Ph.D. 
Thesis: Dendrimer Based Targeted Therapy for CNS Disorders 
 Determined the mechanism of how polyamidoamine (PAMAM) dendrimers 
intrinsically target neuroinflammation at global (systemic) and local (tissue and 
cell) levels in a spectrum of neurological disorders using an integrative 
engineering approach. This knowledge builds the guiding principles for 
designing nanomedicine that can efficiently target and resolve 
neuroinflammation.  
 Studied dendrimer kinetics and uptake mechanisms in multiple models 
ranging from small rodents (mice, rats and rabbits) to a more human-
representative large animal (canine). These studies enabled understanding in 
translating nanomedicine from research into clinics. 
 Developed a novel ex vivo system using neuroscience and immunology appro
aches which addresses the role of ‘activated’ microglial cells as the major 
CNS innate immune cells in neuroinflammation by studying their ability to 
migrate and phagocytose dendrimers. 
 Engineered dendrimer-based intravenous therapeutics (Doxorubicin, GCPII 
inhibitor, MEK pathway inhibitor, etc.) that can target activated 
microglia/macrophages in multiple disease models through bio-conjugation 
chemistry, and achieved controlled release triggered by glutathione 
concentration and pH level. 
Highlights of lab experience 
 Collaborated with research teams composed of researchers from multiple field
s, including neurosurgery, cardiac surgery, engineering, neurology and 
neuroscience. 
 Developed key research results that formed the basis of more than $4 million 
successful NIH-based research funds (R01) and other research funding 
sources. 
 Led and mentored 4 students including master, undergraduate, and high 
school students in developing dendrimer based therapies for various 
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neurological diseases.  
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[10] Nance E, Zhang F, Mishra M, Zhang Z, Kambhampati SP, In vivo mechanism of 
dendrimer-mediated delivery in pediatric brain disorders. Biomaterials. under review 
Manuscript in submission (Papers written, to be submitted) 
[11] Zhang F*, Zhang Z*, Alt J, Kambhampati SP, Nance E, Rojas C, Slusher B, Kannan RM, 
Kannan S. Dendrimer-GCPII Inhibitor Decreases Neuroinflammation and Glutamate 
Excitotoxicity in a Rabbit Model of Cerebral Palsy. Manuscript in preparation. 
[12] Grimm JC*, Zhang F*, Beaty CA, Mishra MK, Magruder JT, Kannan R, Shah A, The 
injury-targeted accumulation and cellular localization of dendrimer particles in an ex-vivo 
ischemia- reperfusion model of acute lung injury. Manuscript in submission. 
[13] Balakrishnan B, Mishra MK, Zhang F, Eberhart C, Romero R, Kannan RM, Kannan S. In 
vivo toxicity of hydroxyl-functionalized PAMAM dendrimers in neonatal rabbit kits. 
Manuscript in submission. 
[14] Alnasser Y, Kambampatti SP, Nance E, Zhang F, Rajbhandari L, Shrestha S, 
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Venkatesan A, Kannan RM, Kannan S. Mechanisms of cellular uptake of dendrimer 
based nanodevices by primary glial cells. 
[15] Nemeth CL, Drummond GT, Mishra MK, Zhang F, Carr P, Kannan RM, Fatemi A, 
Johnston MV, Kannan S, Wilson MA. Quantitative assessment of biodistribution and 
dendrimer-drug uptake in a neonatal mouse model of hypoxic-ischemic encephalopathy. 
Manuscript in preparation. 
IV. PATENTS  
[1] Kannan RM, Tyler B, Zhang F, Mastorakos P, Mishra M, Mangraviti A. APPROACHES 
FOR SYSTEMIC TARGETING OF TUMOR MACROPHAGES IN BRAIN TUMORS, U.S. 
Provisional Application (P13214-01), 2014, filed at The Johns Hopkins University. 
Licensed 
[2] Kannan RM, Kannan, S, Nance E, Blue M, Johnston M, Baumgartner W, Zhang F, 
Wilson MA, Slusher B. DENDRIMER-DRUG DELIVERY SYSTEMS FOR TREATMENT 
OF RETT SYNDROME AND CNS DISORDERS, U.S. Provisional Application (JHU 
C13169), 2015, filed at The Johns Hopkins University. Licensed 
[3] Kannan RM, Kannan, S, Fatemi A, Zhang F, Turk B. NANOPARTICLES FOR THE 
TREATMENT OF LEUKODYSTROPHIES INCLUDING X-LINKED 
ADRENOLEUKODYSTROPHY, U.S. Provisional Application (JHU C13801), 2015, filed 
at The Johns Hopkins University.  
[4] Kannan RM, Hackam D, Kannan S, Nino DF, Zhang F. NANOPARTICLES FOR THE 
DIAGNOSIS AND TREATMENT OF NEONATAL NECROTIZING ENTEROCOLITIS, 
Provisional Application (JHU C13800), 2015, filed at The Johns Hopkins University. 
V. SELECTED PRESENTATIONS 
[1] Zhang F, Mastorakos P, Mishra M, Mangraviti A, Hwang L, Zhou J, Hanes J, Brem H, Olivi 
A, Tyler B, Kannan RM Dendrimer based systemic therapies for the treatment of Glioblastoma. Poster 
session, September, 2015, Seattle, USA 
[2] Zhang F, Mastorakos P, Mishra M, Mangraviti A, Hwang L, Zhou J, Hanes J, Brem H, Olivi 
A, Tyler B, Kannan RM Dendrimer based systemic therapies for the treatment of Glioblastoma. Poster 
session, The Johns Hopkins University Nano-Bio Symposium, April, 2015, Baltimore, USA 
[3] Zhang F, Nance E, Alnasser Y, Kannan RM, Kannan S. Microglia migration and interactions 
with dendrimer in brain in the presence of neuroinflammation. Poster session, Biomedical 
Engineering Society Annual Meeting, Oct, 2014, San Antonio, USA. 
[4] Zhang F, Nance E, Alnasser Y, Kannan RM, Kannan S. Microglia migration and interactions 
with dendrimer in brain in the presence of neuroinflammation. Poster session, Society of 
Neuroscience Conference, Nov. 2014, Washington DC. USA 
[5] Nance E, Zhang F, Balakrishnan B, Mishra M, Kambhampati SP. Mechanism of Nanoparticle-
mediated Therapeutic Delivery in a Rabbit Model of Cerebral Palsy. Poster session, Society of 
Neuroscience Conference, Nov. 2014, Washington DC. USA 
[6] Zhang F, Nance E, Alnasser Y, Kannan RM, Kannan S. Study of Microglia Movement and 
Interactions in Brain Slice of Cerebral Palsy Rabbit Model. Poster session, Pediatric Academic 
Societies Annual Meeting, May, 2014, Vancouver, Canada 
[7] Kannan S, Mishra M, Nance E, Zhang F, Kannan RM. Mechanisms of Nanoparticle Uptake in 
Neuroinflammation-induced Pediatric Brian Injury. Poster session, Society of Critical Care 
Medicine Annual Conference, 2014, San Francisco, USA. Annual Scientific Award 
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[8] Zhang F, Nance E, Alnasser Y, Kannan RM, Kannan S. Microglia migration and interactions 
with dendrimer in brain in the presence of neuroinflammation. Poster session, Johns Hopkins 
Anesthesiology & Critical Care Medicine Annual Meeting, November, 2013, Baltimore, USA 
 
VI. TEACHING/MENTORING 
01/2015-05/2015  Teaching assistant, The Johns Hopkins University, USA 
Course: Micro-and Nano Structured Materials and Devices 
 
01/2013-05/2014  Teaching assistant, The Johns Hopkins University, USA 
Course: Modern Alchemy 
 
08/2010-05/2011  Teaching assistant, Wayne State University, USA 
Course: Fundamentals of Material Science and Engineering.  
 Led scheduling and lecturing the lab section of the course (scheduling 
the whole curriculum, drafting the lecture notes, lab manual, preparing 
and maintaining lab equipment). 
 
Mentored one graduate student (Jiangyu Li, 01/2015-now), two undergraduate students 
(Venkatasai Jasty, 01/2014-10/2014; Josiah Yu, 05/2014-09/2014) and one high school student 
(Fredrick Eisenbiegler, 07/2015-08/2015) for their research in Professor Rangaramanujam M. 
Kannan's lab. 
VII. HONORS/AWARDS 
[1] Donghua Scholarship (equivalent to Outstanding Student), 2009, Shanghai, China 
[2] Outstanding Scientific and Technological Innovation and Research, 2009, Shanghai, 
China 
[3] Academic Excellence Award, 2007 and 2008 2 consecutive times, Shanghai, China 
VIII. RESEARCH FUNDING 
Experimental contributions to the following successful funded grants: 
9/1/2014-6/30/2018  NIH/NHLBI2R01HL091541-20 (Baumgartner & Kannan)  
             
 Excitotoxicity in circulatory arrest-brain injury 
12/1/2013-11/30/2014  Astra Zeneca Corporation AstraZeneca116601 (Kannan & Tyler) 
           
 Dendrimer-based therapies targeted to tumor-associated macrophages in Glioma 
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Biomedical Engineering Society, 2014-present 
Society of Neuroscience, 2014-present 
American Society for Nanomedicine, 2015-present 
X. JOURNAL REVIEWS 
Contributed to manuscript revisions as part of the peer-review process for the following journals: 
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European Journal of Pharmaceutical Sciences 
European Journal of Nanomedicine 
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